# NCEES FE/PE Engineering & Advanced Practice Nursing (FNP & CCRN) — Engineering Economics, Mechanics/Fluids, Critical Care Hemodynamics & Clinical Pharmacology

> Rigorous NCEES Fundamentals/Principles of Engineering (FE/PE), AANP/ANCC Family Nurse Practitioner (FNP), and AACN Critical Care (CCRN) flashcards covering NCEES Engineering Ethics, Engineering Economics (PW, Capitalized Cost, MACRS), Beam Bending, Thermal Stress, Euler Buckling, Mohr's Circle, Carnot & Steady-Flow Thermodynamics, Reynolds Number & Darcy-Weisbach Head Loss, Three-Phase AC Power, Swan-Ganz Hemodynamics (CVP, PAP, PAWP, SVR) & Shock States, Sepsis, STEMI & IABP, ARDSNet, ICP/CPP, DKA, DI/SIADH, ACC/AHA HTN & HFrEF Quadruple GDMT, GINA Asthma, GOLD COPD, ADA Diabetes, IDSA/CDC Antibiotics, USPSTF Screening, Pediatrics, Anemia, and CYP450/Hyperkalemia.

- **Canonical URL:** https://flashcards.world/flashcards/sets/c0c44ccc-d333-44ac-a142-c40f08101356/
- **Markdown URL:** https://flashcards.world/flashcards/sets/c0c44ccc-d333-44ac-a142-c40f08101356.md
- **Level:** advanced
- **Languages:** en → en
- **Total Cards:** 32

## Flashcards (32 Cards)

| # | Front (Term / Prompt) | Back (Definition / Answer) | Example | Multiple-Choice Options |
| :--- | :--- | :--- | :--- | :--- |
| 1 | Under current IDSA, ATS, and CDC guidelines tested on FNP exams, what is the first-line outpatient antibiotic regimen for: (1) Community-Acquired Pneumonia (CAP) in a healthy adult vs. an adult with comorbidities, (2) Uncomplicated Acute Cystitis (UTI) in a non-pregnant woman, (3) Uncomplicated Gonorrhea + Chlamydia, and (4) Primary/Secondary Syphilis? | (1) Outpatient CAP: Healthy adult (no comorbidities) -> Amoxicillin 1 g PO TID or Doxycycline 100 mg PO BID (or Azithromycin ONLY if local pneumococcal macrolide resistance < 25%); Adult WITH comorbidities (heart/lung/liver/renal disease, diabetes, alcoholism, malignancy, asplenia) -> Amoxicillin-Clavulanate (Augmentin) + Macrolide (or Doxycycline) OR monotherapy with a Respiratory Fluoroquinolone (Levofloxacin 750 mg or Moxifloxacin 400 mg daily); (2) Uncomplicated Cystitis -> Nitrofurantoin (Macrobid) 100 mg BID × 5 days (avoid if CrCl < 30 or pyelonephritis), TMP-SMX DS BID × 3 days, or Fosfomycin 3 g × 1 dose; (3) Gonorrhea + Chlamydia -> Ceftriaxone 500 mg IM × 1 (1 g IM if >= 150 kg) + Doxycycline 100 mg PO BID × 7 days (Azithromycin 1 g PO × 1 for Chlamydia in pregnancy); (4) Primary/Secondary/Early Latent Syphilis -> Benzathine Penicillin G (Bicillin L-A) 2.4 million units IM × 1 — Classic FNP antibiotic pearls: (1) Ciprofloxacin is NOT a 'respiratory fluoroquinolone' (it lacks adequate *S. pneumoniae* coverage; only Levofloxacin, Moxifloxacin, and Gemifloxacin are respiratory FQs!). (2) Nitrofurantoin concentrates only in the lower urinary tract (bladder urine), never in renal parenchyma—so it is strictly contraindicated in pyelonephritis (use Ciprofloxacin/Levofloxacin or Ceftriaxone + TMP-SMX) and when CrCl < 30 mL/min (also avoid in late pregnancy near term/G6PD deficiency due to hemolytic anemia). (3) Under updated CDC STI guidelines, Ceftriaxone for Gonorrhea increased to 500 mg IM × 1 (1 g if >= 150 kg), and Doxycycline 100 mg BID × 7 days replaced Azithromycin as preferred first-line therapy for non-pregnant Chlamydia. (4) Penicillin G is the ONLY effective therapy for Syphilis in pregnancy (penicillin-allergic pregnant women MUST undergo desensitization). | Classic FNP antibiotic pearls: (1) Ciprofloxacin is NOT a 'respiratory fluoroquinolone' (it lacks adequate *S. pneumoniae* coverage; only Levofloxacin, Moxifloxacin, and Gemifloxacin are respiratory FQs!). (2) Nitrofurantoin concentrates only in the lower urinary tract (bladder urine), never in renal parenchyma—so it is strictly contraindicated in pyelonephritis (use Ciprofloxacin/Levofloxacin or Ceftriaxone + TMP-SMX) and when CrCl < 30 mL/min (also avoid in late pregnancy near term/G6PD deficiency due to hemolytic anemia). (3) Under updated CDC STI guidelines, Ceftriaxone for Gonorrhea increased to 500 mg IM × 1 (1 g if >= 150 kg), and Doxycycline 100 mg BID × 7 days replaced Azithromycin as preferred first-line therapy for non-pregnant Chlamydia. (4) Penicillin G is the ONLY effective therapy for Syphilis in pregnancy (penicillin-allergic pregnant women MUST undergo desensitization). | A) (1) Outpatient CAP: Healthy adult (no comorbidities) -> Amoxicillin 1 g PO TID or Doxycycline 100 mg PO BID (or Azithromycin ONLY if local pneumococcal macrolide resistance < 25%); Adult WITH comorbidities (heart/lung/liver/renal disease, diabetes, alcoholism, malignancy, asplenia) -> Amoxicillin-Clavulanate (Augmentin) + Macrolide (or Doxycycline) OR monotherapy with a Respiratory Fluoroquinolone (Levofloxacin 750 mg or Moxifloxacin 400 mg daily); (2) Uncomplicated Cystitis -> Nitrofurantoin (Macrobid) 100 mg BID × 5 days (avoid if CrCl < 30 or pyelonephritis), TMP-SMX DS BID × 3 days, or Fosfomycin 3 g × 1 dose; (3) Gonorrhea + Chlamydia -> Ceftriaxone 500 mg IM × 1 (1 g IM if >= 150 kg) + Doxycycline 100 mg PO BID × 7 days (Azithromycin 1 g PO × 1 for Chlamydia in pregnancy); (4) Primary/Secondary/Early Latent Syphilis -> Benzathine Penicillin G (Bicillin L-A) 2.4 million units IM × 1 — Classic FNP antibiotic pearls: (1) Ciprofloxacin is NOT a 'respiratory fluoroquinolone' (it lacks adequate *S. pneumoniae* coverage; only Levofloxacin, Moxifloxacin, and Gemifloxacin are respiratory FQs!). (2) Nitrofurantoin concentrates only in the lower urinary tract (bladder urine), never in renal parenchyma—so it is strictly contraindicated in pyelonephritis (use Ciprofloxacin/Levofloxacin or Ceftriaxone + TMP-SMX) and when CrCl < 30 mL/min (also avoid in late pregnancy near term/G6PD deficiency due to hemolytic anemia). (3) Under updated CDC STI guidelines, Ceftriaxone for Gonorrhea increased to 500 mg IM × 1 (1 g if >= 150 kg), and Doxycycline 100 mg BID × 7 days replaced Azithromycin as preferred first-line therapy for non-pregnant Chlamydia. (4) Penicillin G is the ONLY effective therapy for Syphilis in pregnancy (penicillin-allergic pregnant women MUST undergo desensitization). ✓; B) Pregnant patients with syphilis and a penicillin allergy should be treated with Doxycycline for 14 days; C) Outpatient CAP in a comorbidity-free adult should always be treated with Ciprofloxacin (which has NO reliable activity against Streptococcus pneumoniae!); Gonorrhea is treated with Ceftriaxone 250 mg IM; D) Nitrofurantoin (Macrobid) is the drug of choice for acute febrile pyelonephritis and prostatitis because it achieves high renal parenchymal tissue levels |
| 2 | In FE Mechanics of Materials (Mohr's Circle for 2D Plane Stress), a structural element is subjected to normal stresses sigma_x = +80 MPa (tension), sigma_y = -20 MPa (compression), and shear stress tau_xy = 120 MPa. Calculate the average normal stress (sigma_avg), the maximum in-plane shear stress (tau_max / Radius R of Mohr's Circle), and the major and minor Principal Stresses (sigma_1, sigma_2). | sigma_avg = +30 MPa ((80 + (-20)) / 2); Maximum In-Plane Shear Stress tau_max = R = 130 MPa (sqrt(((80 - (-20))/2)^2 + 120^2) = sqrt(50^2 + 120^2)); Principal Stresses are sigma_1 = +160 MPa (30 + 130) and sigma_2 = -100 MPa (30 - 130) — On Mohr's Circle: (1) Center of the circle is sigma_avg = (sigma_x + sigma_y) / 2 = (80 - 20) / 2 = +30 MPa. (2) Radius R = tau_max = sqrt([(sigma_x - sigma_y) / 2]^2 + tau_xy^2) = sqrt([(80 - (-20)) / 2]^2 + 120^2) = sqrt(50^2 + 120^2) = sqrt(2,500 + 14,400) = sqrt(16,900) = 130 MPa (a 5-12-13 right triangle!). (3) Principal stresses are sigma_1,2 = sigma_avg ± R = 30 ± 130 -> sigma_1 = +160 MPa and sigma_2 = -100 MPa. | On Mohr's Circle: (1) Center of the circle is sigma_avg = (sigma_x + sigma_y) / 2 = (80 - 20) / 2 = +30 MPa. (2) Radius R = tau_max = sqrt([(sigma_x - sigma_y) / 2]^2 + tau_xy^2) = sqrt([(80 - (-20)) / 2]^2 + 120^2) = sqrt(50^2 + 120^2) = sqrt(2,500 + 14,400) = sqrt(16,900) = 130 MPa (a 5-12-13 right triangle!). (3) Principal stresses are sigma_1,2 = sigma_avg ± R = 30 ± 130 -> sigma_1 = +160 MPa and sigma_2 = -100 MPa. | A) sigma_avg = +50 MPa; tau_max = 120 MPa; Principal Stresses are sigma_1 = +170 MPa and sigma_2 = -70 MPa; B) sigma_avg = +30 MPa; tau_max = 125 MPa (sqrt(30^2 + 120^2)); Principal Stresses are +155 MPa and -95 MPa; C) sigma_avg = +60 MPa; tau_max = 130 MPa; Principal Stresses are +190 MPa and -70 MPa; D) sigma_avg = +30 MPa ((80 + (-20)) / 2); Maximum In-Plane Shear Stress tau_max = R = 130 MPa (sqrt(((80 - (-20))/2)^2 + 120^2) = sqrt(50^2 + 120^2)); Principal Stresses are sigma_1 = +160 MPa (30 + 130) and sigma_2 = -100 MPa (30 - 130) — On Mohr's Circle: (1) Center of the circle is sigma_avg = (sigma_x + sigma_y) / 2 = (80 - 20) / 2 = +30 MPa. (2) Radius R = tau_max = sqrt([(sigma_x - sigma_y) / 2]^2 + tau_xy^2) = sqrt([(80 - (-20)) / 2]^2 + 120^2) = sqrt(50^2 + 120^2) = sqrt(2,500 + 14,400) = sqrt(16,900) = 130 MPa (a 5-12-13 right triangle!). (3) Principal stresses are sigma_1,2 = sigma_avg ± R = 30 ± 130 -> sigma_1 = +160 MPa and sigma_2 = -100 MPa. ✓ |
| 3 | Compare the Swan-Ganz hemodynamic profiles (CVP, PAWP, CO/CI, SVR, and SvO_2) of (1) Hypovolemic Shock, (2) Cardiogenic Shock, (3) Early Hyperdynamic (Warm) Septic Shock, (4) Neurogenic Shock, and (5) Obstructive Cardiac Tamponade. | (1) Hypovolemic: Low CVP, Low PAWP, Low CO/CI, High SVR, Low SvO_2; (2) Cardiogenic: High CVP, High PAWP (> 18 mmHg), Low CO/CI (< 2.2 L/min/m^2), High SVR, Low SvO_2; (3) Warm Septic: Low/Normal CVP & PAWP, High/Normal CO/CI, Markedly LOW SVR (< 800), High/Normal SvO_2 (impaired cellular O_2 extraction); (4) Neurogenic (SCI above T6): Low BP, Low CVP/PAWP, LOW SVR, and BRADYCARDIA (unopposed vagal tone) with warm dry skin; (5) Cardiac Tamponade: High CVP, Low CO/CI, High SVR, and EQUALIZATION of diastolic pressures (CVP ≈ PAD ≈ PAWP within 2–3 mmHg) with Beck's Triad and pulsus paradoxus (> 10 mmHg inspiratory SBP drop) — Hemodynamic shock differentiation is tested on multiple CCRN items: (1) SVR is HIGH (compensatory sympathetic vasoconstriction) in Hypovolemic, Cardiogenic, and Obstructive shock, and LOW (vasodilation) ONLY in Distributive shock (Septic, Anaphylactic, Neurogenic). (2) Preload (CVP & PAWP) is HIGH in Cardiogenic shock (pump failure backs fluid up into the lungs, PAWP > 18 mmHg) and LOW in Hypovolemic/Distributive shock. (3) Neurogenic shock (spinal cord injury above T6) is the ONLY shock state that classically presents with BRADYCARDIA + warm, dry skin due to loss of sympathetic outflow. (4) Cardiac tamponade equalizes CVP = PAD = PAWP. | Hemodynamic shock differentiation is tested on multiple CCRN items: (1) SVR is HIGH (compensatory sympathetic vasoconstriction) in Hypovolemic, Cardiogenic, and Obstructive shock, and LOW (vasodilation) ONLY in Distributive shock (Septic, Anaphylactic, Neurogenic). (2) Preload (CVP & PAWP) is HIGH in Cardiogenic shock (pump failure backs fluid up into the lungs, PAWP > 18 mmHg) and LOW in Hypovolemic/Distributive shock. (3) Neurogenic shock (spinal cord injury above T6) is the ONLY shock state that classically presents with BRADYCARDIA + warm, dry skin due to loss of sympathetic outflow. (4) Cardiac tamponade equalizes CVP = PAD = PAWP. | A) Hypovolemic Shock presents with elevated CVP, elevated PAWP, and SvO_2 > 85%; B) Cardiogenic Shock presents with Low PAWP and Low SVR; Septic Shock presents with High SVR and Bradycardia; C) (1) Hypovolemic: Low CVP, Low PAWP, Low CO/CI, High SVR, Low SvO_2; (2) Cardiogenic: High CVP, High PAWP (> 18 mmHg), Low CO/CI (< 2.2 L/min/m^2), High SVR, Low SvO_2; (3) Warm Septic: Low/Normal CVP & PAWP, High/Normal CO/CI, Markedly LOW SVR (< 800), High/Normal SvO_2 (impaired cellular O_2 extraction); (4) Neurogenic (SCI above T6): Low BP, Low CVP/PAWP, LOW SVR, and BRADYCARDIA (unopposed vagal tone) with warm dry skin; (5) Cardiac Tamponade: High CVP, Low CO/CI, High SVR, and EQUALIZATION of diastolic pressures (CVP ≈ PAD ≈ PAWP within 2–3 mmHg) with Beck's Triad and pulsus paradoxus (> 10 mmHg inspiratory SBP drop) — Hemodynamic shock differentiation is tested on multiple CCRN items: (1) SVR is HIGH (compensatory sympathetic vasoconstriction) in Hypovolemic, Cardiogenic, and Obstructive shock, and LOW (vasodilation) ONLY in Distributive shock (Septic, Anaphylactic, Neurogenic). (2) Preload (CVP & PAWP) is HIGH in Cardiogenic shock (pump failure backs fluid up into the lungs, PAWP > 18 mmHg) and LOW in Hypovolemic/Distributive shock. (3) Neurogenic shock (spinal cord injury above T6) is the ONLY shock state that classically presents with BRADYCARDIA + warm, dry skin due to loss of sympathetic outflow. (4) Cardiac tamponade equalizes CVP = PAD = PAWP. ✓; D) Neurogenic Shock presents with severe tachycardia, cool clammy skin, and SVR > 1,500 dyn·s·cm^-5 |
| 4 | Under the ACC/AHA Blood Cholesterol Guidelines tested on the FNP boards, what are the 4 primary Statin Benefit Groups, which specific statins and doses qualify as High-Intensity Statin Therapy (lowering LDL-C by >= 50%), and how is an Arterial Blood Gas (ABG) with pH = 7.28, PaCO_2 = 24 mmHg, and HCO_3^- = 10 mEq/L interpreted using Winter's Formula? | The 4 Statin Benefit Groups are: (1) Clinical ASCVD, (2) Severe Primary Hypercholesterolemia (LDL-C >= 190 mg/dL — no 10-yr ASCVD risk score needed!), (3) Diabetes Mellitus aged 40–75 with LDL-C 70–189 mg/dL, and (4) Adults aged 40–75 without diabetes with LDL-C 70–189 mg/dL and 10-yr ASCVD risk >= 7.5%; ONLY Atorvastatin 40–80 mg and Rosuvastatin 20–40 mg daily are High-Intensity Statins (>= 50% LDL-C reduction); on the ABG (pH 7.28 < 7.35, HCO_3^- 10 < 22), the primary disorder is Partially Compensated Metabolic Acidosis, and by Winter's Formula Expected PaCO_2 = 1.5(HCO_3^-) + 8 ± 2 = 1.5(10) + 8 ± 2 = 23 ± 2 mmHg (21–25 mmHg), confirming appropriate respiratory compensation (PaCO_2 = 24 mmHg) — (1) Memorize the ONLY two High-Intensity Statin regimens (lowering LDL-C >= 50%): Atorvastatin 40–80 mg and Rosuvastatin 20–40 mg (indicated immediately for Clinical ASCVD or baseline LDL-C >= 190 mg/dL). (2) For ABG interpretation in Metabolic Acidosis (low pH < 7.35, low HCO_3^- < 22 mEq/L), Winter's Formula checks whether hyperventilation is appropriate or if a secondary respiratory disorder coexists: Expected PaCO_2 = 1.5(HCO_3^-) + 8 ± 2. Here, 1.5(10) + 8 = 23 ± 2 (21–25 mmHg), which matches the measured PaCO_2 of 24 mmHg. | (1) Memorize the ONLY two High-Intensity Statin regimens (lowering LDL-C >= 50%): Atorvastatin 40–80 mg and Rosuvastatin 20–40 mg (indicated immediately for Clinical ASCVD or baseline LDL-C >= 190 mg/dL). (2) For ABG interpretation in Metabolic Acidosis (low pH < 7.35, low HCO_3^- < 22 mEq/L), Winter's Formula checks whether hyperventilation is appropriate or if a secondary respiratory disorder coexists: Expected PaCO_2 = 1.5(HCO_3^-) + 8 ± 2. Here, 1.5(10) + 8 = 23 ± 2 (21–25 mmHg), which matches the measured PaCO_2 of 24 mmHg. | A) The 4 Statin Benefit Groups are: (1) Clinical ASCVD, (2) Severe Primary Hypercholesterolemia (LDL-C >= 190 mg/dL — no 10-yr ASCVD risk score needed!), (3) Diabetes Mellitus aged 40–75 with LDL-C 70–189 mg/dL, and (4) Adults aged 40–75 without diabetes with LDL-C 70–189 mg/dL and 10-yr ASCVD risk >= 7.5%; ONLY Atorvastatin 40–80 mg and Rosuvastatin 20–40 mg daily are High-Intensity Statins (>= 50% LDL-C reduction); on the ABG (pH 7.28 < 7.35, HCO_3^- 10 < 22), the primary disorder is Partially Compensated Metabolic Acidosis, and by Winter's Formula Expected PaCO_2 = 1.5(HCO_3^-) + 8 ± 2 = 1.5(10) + 8 ± 2 = 23 ± 2 mmHg (21–25 mmHg), confirming appropriate respiratory compensation (PaCO_2 = 24 mmHg) — (1) Memorize the ONLY two High-Intensity Statin regimens (lowering LDL-C >= 50%): Atorvastatin 40–80 mg and Rosuvastatin 20–40 mg (indicated immediately for Clinical ASCVD or baseline LDL-C >= 190 mg/dL). (2) For ABG interpretation in Metabolic Acidosis (low pH < 7.35, low HCO_3^- < 22 mEq/L), Winter's Formula checks whether hyperventilation is appropriate or if a secondary respiratory disorder coexists: Expected PaCO_2 = 1.5(HCO_3^-) + 8 ± 2. Here, 1.5(10) + 8 = 23 ± 2 (21–25 mmHg), which matches the measured PaCO_2 of 24 mmHg. ✓; B) Only patients with existing myocardial infarction qualify for High-Intensity Statin therapy; the ABG shows Mixed Metabolic and Respiratory Acidosis; C) Simvastatin 40 mg and Pravastatin 80 mg are High-Intensity Statins; the ABG shows Uncompensated Respiratory Alkalosis; D) Patients with LDL-C >= 190 mg/dL require a Coronary Artery Calcium (CAC) score before starting a statin; Winter's Formula is Expected PaCO_2 = 2.5(HCO_3^-) + 12 |
| 5 | In FE Statics and Mechanics of Materials, a simply supported beam of span L = 6.0 m carries a uniform distributed load w = 12 kN/m across its entire length. The beam has a rectangular cross-section of width b = 0.15 m and height h = 0.30 m. What are the maximum bending moment (M_max) at midspan, the centroidal area moment of inertia (I_x), and the maximum flexural bending stress (sigma_max)? | M_max = 54.0 kN·m (wL^2 / 8 = 12 × 6^2 / 8); I_x = 3.375 × 10^-4 m^4 (bh^3 / 12 = 0.15 × 0.30^3 / 12); sigma_max = 24.0 MPa (M_max × c / I_x = 54,000 N·m × 0.15 m / 3.375 × 10^-4 m^4) — (1) For a simply supported beam with uniform load w over span L, maximum bending moment at midspan is M_max = wL^2 / 8 = 12(6.0)^2 / 8 = 54.0 kN·m (54,000 N·m). (2) Centroidal moment of inertia of a rectangle is I = bh^3 / 12 = (0.15)(0.30)^3 / 12 = 0.0003375 m^4 (3.375 × 10^-4 m^4). (3) Extreme fiber distance from neutral axis is c = h / 2 = 0.15 m, so maximum bending stress sigma_max = M_max × c / I = (54,000 × 0.15) / 0.0003375 = 24,000,000 Pa = 24.0 MPa. | (1) For a simply supported beam with uniform load w over span L, maximum bending moment at midspan is M_max = wL^2 / 8 = 12(6.0)^2 / 8 = 54.0 kN·m (54,000 N·m). (2) Centroidal moment of inertia of a rectangle is I = bh^3 / 12 = (0.15)(0.30)^3 / 12 = 0.0003375 m^4 (3.375 × 10^-4 m^4). (3) Extreme fiber distance from neutral axis is c = h / 2 = 0.15 m, so maximum bending stress sigma_max = M_max × c / I = (54,000 × 0.15) / 0.0003375 = 24,000,000 Pa = 24.0 MPa. | A) M_max = 36.0 kN·m; I_x = 3.375 × 10^-4 m^4; sigma_max = 16.0 MPa; B) M_max = 54.0 kN·m (wL^2 / 8 = 12 × 6^2 / 8); I_x = 3.375 × 10^-4 m^4 (bh^3 / 12 = 0.15 × 0.30^3 / 12); sigma_max = 24.0 MPa (M_max × c / I_x = 54,000 N·m × 0.15 m / 3.375 × 10^-4 m^4) — (1) For a simply supported beam with uniform load w over span L, maximum bending moment at midspan is M_max = wL^2 / 8 = 12(6.0)^2 / 8 = 54.0 kN·m (54,000 N·m). (2) Centroidal moment of inertia of a rectangle is I = bh^3 / 12 = (0.15)(0.30)^3 / 12 = 0.0003375 m^4 (3.375 × 10^-4 m^4). (3) Extreme fiber distance from neutral axis is c = h / 2 = 0.15 m, so maximum bending stress sigma_max = M_max × c / I = (54,000 × 0.15) / 0.0003375 = 24,000,000 Pa = 24.0 MPa. ✓; C) M_max = 108.0 kN·m (wL^2 / 4); I_x = 3.375 × 10^-4 m^4; sigma_max = 48.0 MPa; D) M_max = 54.0 kN·m; I_x = 6.75 × 10^-4 m^4 (bh^3 / 6); sigma_max = 12.0 MPa |
| 6 | A 74-year-old patient taking Warfarin (Coumadin) for mechanical mitral valve replacement (target INR 2.5–3.5) is prescribed Trimethoprim-Sulfamethoxazole (TMP-SMX / Bactrim) for a UTI. Five days later, the patient presents with gross hematuria and an INR of 9.2. Explain the Cytochrome P450 mechanism of this interaction, distinguish CYP450 Inducers ('CRAP GPS') from Inhibitors ('SICKFACES.COM'), and state the specific reversal antidotes for Warfarin, Unfractionated Heparin, Dabigatran, and Apixaban/Rivaroxaban. | TMP-SMX (Sulfonamide), Metronidazole, Fluconazole, Amiodarone, Ciprofloxacin, Macrolides (Erythromycin/Clarithromycin), Cimetidine, Valproate, Isoniazid, and Grapefruit juice are potent CYP450 INHIBITORS ('SICKFACES.COM') that block hepatic metabolism of Warfarin (CYP2C9), causing dangerous INR spikes and bleeding; conversely, Carbamazepine, Rifampin, Alcohol (chronic), Phenytoin, Griseofulvin, Phenobarbital, and St. John's Wort are CYP450 INDUCERS ('CRAP GPS') that accelerate Warfarin metabolism, lowering INR and causing thrombosis; Specific Reversal Antidotes: Warfarin -> Vitamin K (Phytonadione) + 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra) for life-threatening bleeding; Unfractionated Heparin -> Protamine Sulfate; Dabigatran (direct thrombin inhibitor) -> Idarucizumab (Praxbind); Apixaban / Rivaroxaban (Factor Xa inhibitors) -> Andexanet alfa (Andexxa) or 4F-PCC — Drug-drug interactions with Warfarin are tested on both FNP and CCRN exams: (1) Starting a CYP450 Inhibitor ('SICKFACES.COM' + Amiodarone — especially TMP-SMX/Bactrim, Metronidazole, Fluconazole, Macrolides, Ciprofloxacin) inhibits Warfarin clearance and spikes the INR! (2) Starting a CYP450 Inducer ('CRAP GPS' — Carbamazepine, Rifampin, chronic Alcohol, Phenytoin, Griseofulvin, Phenobarbital, St. John's Wort) speeds up clearance and drops the INR (and causes oral contraceptive failure!). (3) Reversal agents: Warfarin = Vitamin K + 4F-PCC (faster than FFP); Heparin = Protamine; Dabigatran = Idarucizumab; Factor Xa inhibitors (-xabans) = Andexanet alfa. | Drug-drug interactions with Warfarin are tested on both FNP and CCRN exams: (1) Starting a CYP450 Inhibitor ('SICKFACES.COM' + Amiodarone — especially TMP-SMX/Bactrim, Metronidazole, Fluconazole, Macrolides, Ciprofloxacin) inhibits Warfarin clearance and spikes the INR! (2) Starting a CYP450 Inducer ('CRAP GPS' — Carbamazepine, Rifampin, chronic Alcohol, Phenytoin, Griseofulvin, Phenobarbital, St. John's Wort) speeds up clearance and drops the INR (and causes oral contraceptive failure!). (3) Reversal agents: Warfarin = Vitamin K + 4F-PCC (faster than FFP); Heparin = Protamine; Dabigatran = Idarucizumab; Factor Xa inhibitors (-xabans) = Andexanet alfa. | A) TMP-SMX is a CYP450 Inducer that lowers the INR; Rifampin and St. John's Wort are CYP450 Inhibitors that raise the INR; B) TMP-SMX (Sulfonamide), Metronidazole, Fluconazole, Amiodarone, Ciprofloxacin, Macrolides (Erythromycin/Clarithromycin), Cimetidine, Valproate, Isoniazid, and Grapefruit juice are potent CYP450 INHIBITORS ('SICKFACES.COM') that block hepatic metabolism of Warfarin (CYP2C9), causing dangerous INR spikes and bleeding; conversely, Carbamazepine, Rifampin, Alcohol (chronic), Phenytoin, Griseofulvin, Phenobarbital, and St. John's Wort are CYP450 INDUCERS ('CRAP GPS') that accelerate Warfarin metabolism, lowering INR and causing thrombosis; Specific Reversal Antidotes: Warfarin -> Vitamin K (Phytonadione) + 4-Factor Prothrombin Complex Concentrate (4F-PCC / Kcentra) for life-threatening bleeding; Unfractionated Heparin -> Protamine Sulfate; Dabigatran (direct thrombin inhibitor) -> Idarucizumab (Praxbind); Apixaban / Rivaroxaban (Factor Xa inhibitors) -> Andexanet alfa (Andexxa) or 4F-PCC — Drug-drug interactions with Warfarin are tested on both FNP and CCRN exams: (1) Starting a CYP450 Inhibitor ('SICKFACES.COM' + Amiodarone — especially TMP-SMX/Bactrim, Metronidazole, Fluconazole, Macrolides, Ciprofloxacin) inhibits Warfarin clearance and spikes the INR! (2) Starting a CYP450 Inducer ('CRAP GPS' — Carbamazepine, Rifampin, chronic Alcohol, Phenytoin, Griseofulvin, Phenobarbital, St. John's Wort) speeds up clearance and drops the INR (and causes oral contraceptive failure!). (3) Reversal agents: Warfarin = Vitamin K + 4F-PCC (faster than FFP); Heparin = Protamine; Dabigatran = Idarucizumab; Factor Xa inhibitors (-xabans) = Andexanet alfa. ✓; C) Warfarin overdose is reversed with Protamine Sulfate, and Heparin overdose is reversed with Vitamin K; D) Dabigatran is a Factor Xa inhibitor reversed with Flumazenil, and Apixaban is reversed with Idarucizumab |
| 7 | In FE Mechanics of Materials, a structural steel rod (Modulus of Elasticity E = 200 GPa, coefficient of thermal expansion alpha = 12 × 10^-6 /°C, length L = 2.5 m, cross-sectional area A = 400 mm^2) is rigidly fixed between two immovable walls at 20°C. If the temperature of the rod increases to 70°C (Delta_T = +50°C), what is the resulting thermal stress in the rod, and how does the Euler critical buckling load P_cr change if a column's effective length KL is doubled? | Thermal Stress = 120 MPa in compression (sigma = -E × alpha × Delta_T = -200 × 10^9 Pa × 12 × 10^-6 /°C × 50°C = -120 × 10^6 Pa, independent of length L and area A); under Euler's buckling formula P_cr = pi^2 E I / (KL)^2, doubling the effective length KL reduces the critical buckling load P_cr to ONE-FOURTH (25%) of its original value — (1) For a fully constrained axial member subjected to temperature rise Delta_T, setting total deformation delta = (PL / AE) + alpha(Delta_T)L = 0 yields compressive stress sigma = P / A = -E × alpha × Delta_T = -(200 × 10^9)(12 × 10^-6)(50) = -120 MPa (notice that L and A cancel out!). (2) Euler's column buckling formula is P_cr = pi^2 E I_min / (KL)^2, which is inversely proportional to the SQUARE of effective length KL—so doubling KL (or switching from pinned-pinned K = 1.0 to fixed-free flagpole K = 2.0) divides P_cr by 4. | (1) For a fully constrained axial member subjected to temperature rise Delta_T, setting total deformation delta = (PL / AE) + alpha(Delta_T)L = 0 yields compressive stress sigma = P / A = -E × alpha × Delta_T = -(200 × 10^9)(12 × 10^-6)(50) = -120 MPa (notice that L and A cancel out!). (2) Euler's column buckling formula is P_cr = pi^2 E I_min / (KL)^2, which is inversely proportional to the SQUARE of effective length KL—so doubling KL (or switching from pinned-pinned K = 1.0 to fixed-free flagpole K = 2.0) divides P_cr by 4. | A) Thermal Stress = 300 MPa in tension; doubling the effective length KL reduces the Euler buckling load P_cr by half (50%); B) Thermal Stress = 48 MPa in compression (dividing by length L = 2.5 m); Euler buckling load is independent of column end conditions; C) Thermal Stress = 0 MPa because the rod cannot expand; doubling KL quadruples P_cr; D) Thermal Stress = 120 MPa in compression (sigma = -E × alpha × Delta_T = -200 × 10^9 Pa × 12 × 10^-6 /°C × 50°C = -120 × 10^6 Pa, independent of length L and area A); under Euler's buckling formula P_cr = pi^2 E I / (KL)^2, doubling the effective length KL reduces the critical buckling load P_cr to ONE-FOURTH (25%) of its original value — (1) For a fully constrained axial member subjected to temperature rise Delta_T, setting total deformation delta = (PL / AE) + alpha(Delta_T)L = 0 yields compressive stress sigma = P / A = -E × alpha × Delta_T = -(200 × 10^9)(12 × 10^-6)(50) = -120 MPa (notice that L and A cancel out!). (2) Euler's column buckling formula is P_cr = pi^2 E I_min / (KL)^2, which is inversely proportional to the SQUARE of effective length KL—so doubling KL (or switching from pinned-pinned K = 1.0 to fixed-free flagpole K = 2.0) divides P_cr by 4. ✓ |
| 8 | In FNP Pediatrics, compare the clinical presentation, diagnostic criteria, and urgent management of (1) Kawasaki Disease, (2) Developmental Dysplasia of the Hip (DDH) vs. Slipped Capital Femoral Epiphysis (SCFE), and (3) Pyloric Stenosis vs. Intussusception. | (1) Kawasaki Disease: Fever for >= 5 DAYS plus >= 4 of 5 'CRASH' criteria (Bilateral non-exudative Conjunctivitis, Polymorphous Rash, Acral extremity edema/erythema/desquamation, Strawberry tongue/oral mucositis, unilateral Cervical lymphadenopathy >= 1.5 cm)—treat urgently with high-dose IVIG (2 g/kg) + Aspirin to prevent coronary artery aneurysms (monitored by echocardiogram); (2) DDH: infant with asymmetric gluteal skin folds and positive Barlow/Ortolani clicks -> diagnose by Hip Ultrasound (< 4–6 months, before femoral head ossifies) and treat with Pavlik harness; SCFE: obese adolescent (10–16 yrs) presenting with limp and referred medial KNEE/thigh pain + obligatory external rotation on hip flexion -> frog-leg lateral hip X-ray ('ice cream slipping off cone'), immediate non-weight-bearing on crutches, and urgent surgical pinning; (3) Pyloric Stenosis: 3-to-6-week-old infant with projectile NON-BILIOUS vomiting after feeds and palpable right upper quadrant 'olive-shaped' mass (hypochloremic, hypokalemic metabolic alkalosis); Intussusception: 6-to-36-month-old with sudden paroxysmal colicky abdominal pain (drawing knees to chest), 'currant jelly' (blood/mucus) stools, and sausage-shaped RUQ mass ('target sign' on ultrasound, treated/diagnosed via air or hydrostatic contrast enema) — Every single one of these pediatric emergencies is a classic FNP board question: (1) Kawasaki Disease is the major exception where high-dose Aspirin + IVIG is used in a child (to prevent coronary artery aneurysms). (2) Always examine the HIP in any adolescent (especially obese 10–16 yr old) complaining of KNEE pain (obturator nerve referred pain in SCFE!). (3) In infants < 4–6 months, order a Hip Ultrasound (not X-ray) for DDH because the femoral head is still cartilaginous. | Every single one of these pediatric emergencies is a classic FNP board question: (1) Kawasaki Disease is the major exception where high-dose Aspirin + IVIG is used in a child (to prevent coronary artery aneurysms). (2) Always examine the HIP in any adolescent (especially obese 10–16 yr old) complaining of KNEE pain (obturator nerve referred pain in SCFE!). (3) In infants < 4–6 months, order a Hip Ultrasound (not X-ray) for DDH because the femoral head is still cartilaginous. | A) (1) Kawasaki Disease: Fever for >= 5 DAYS plus >= 4 of 5 'CRASH' criteria (Bilateral non-exudative Conjunctivitis, Polymorphous Rash, Acral extremity edema/erythema/desquamation, Strawberry tongue/oral mucositis, unilateral Cervical lymphadenopathy >= 1.5 cm)—treat urgently with high-dose IVIG (2 g/kg) + Aspirin to prevent coronary artery aneurysms (monitored by echocardiogram); (2) DDH: infant with asymmetric gluteal skin folds and positive Barlow/Ortolani clicks -> diagnose by Hip Ultrasound (< 4–6 months, before femoral head ossifies) and treat with Pavlik harness; SCFE: obese adolescent (10–16 yrs) presenting with limp and referred medial KNEE/thigh pain + obligatory external rotation on hip flexion -> frog-leg lateral hip X-ray ('ice cream slipping off cone'), immediate non-weight-bearing on crutches, and urgent surgical pinning; (3) Pyloric Stenosis: 3-to-6-week-old infant with projectile NON-BILIOUS vomiting after feeds and palpable right upper quadrant 'olive-shaped' mass (hypochloremic, hypokalemic metabolic alkalosis); Intussusception: 6-to-36-month-old with sudden paroxysmal colicky abdominal pain (drawing knees to chest), 'currant jelly' (blood/mucus) stools, and sausage-shaped RUQ mass ('target sign' on ultrasound, treated/diagnosed via air or hydrostatic contrast enema) — Every single one of these pediatric emergencies is a classic FNP board question: (1) Kawasaki Disease is the major exception where high-dose Aspirin + IVIG is used in a child (to prevent coronary artery aneurysms). (2) Always examine the HIP in any adolescent (especially obese 10–16 yr old) complaining of KNEE pain (obturator nerve referred pain in SCFE!). (3) In infants < 4–6 months, order a Hip Ultrasound (not X-ray) for DDH because the femoral head is still cartilaginous. ✓; B) DDH in a 6-week-old newborn is diagnosed by plain AP pelvic X-ray, and SCFE is treated with 6 weeks of physical therapy and ibuprofen; C) Kawasaki Disease is a viral exanthem treated with oral corticosteroids alone, and Aspirin is strictly contraindicated in Kawasaki Disease; D) Pyloric stenosis causes bilious green vomiting and hyperkalemic metabolic acidosis |
| 9 | Under the Global Initiative for Asthma (GINA) guidelines and the Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines tested on FNP boards, why did GINA eliminate SABA-only (Albuterol monotherapy) treatment for Step 1 adult/adolescent asthma, what is GINA Track 1 preferred therapy, and how does GOLD's 'ABE' tool guide initial COPD inhalers? | GINA eliminated SABA-only monotherapy for asthma because regular or frequent SABA use without an Inhaled Corticosteroid (ICS) downregulates beta-2 receptors, increases airway hyperresponsiveness, and increases severe exacerbations and death; GINA Track 1 (Preferred across Steps 1–5) uses low-dose ICS-Formoterol (e.g., Budesonide-Formoterol / Symbicort) as the reliever (as-needed only in Steps 1–2, and as daily Maintenance And Reliever Therapy [MART] in Steps 3–5); in GOLD COPD (post-bronchodilator FEV_1/FVC < 0.70): Group A (0–1 moderate exacerbations, low symptoms mMRC 0–1 / CAT < 10) -> single bronchodilator; Group B (0–1 moderate exacerbations, high symptoms mMRC >= 2 or CAT >= 10) -> LABA + LAMA; Group E (>= 2 moderate exacerbations or >= 1 hospitalization) -> LABA + LAMA (adding ICS for Triple Therapy LABA + LAMA + ICS if blood eosinophils >= 300 cells/uL) — Never confuse Asthma (GINA) and COPD (GOLD) inhaler rules on FNP exams: (1) In Asthma, NEVER prescribe a LABA without an ICS (FDA Black Box Warning for asthma-related death), and under current GINA guidelines, do not treat even mild Step 1 asthma with SABA alone—use as-needed low-dose ICS-Formoterol (Track 1) or take an ICS whenever SABA is taken (Track 2). (2) In COPD (irreversible airflow limitation: post-bronchodilator FEV_1/FVC < 0.70), long-acting bronchodilators (LABA + LAMA) are the backbone for Groups B and E, while ICS is NEVER used as monotherapy and is added (Triple Therapy: LABA + LAMA + ICS) primarily in Group E patients with blood eosinophils >= 300 cells/uL (or >= 100 cells/uL with recurrent exacerbations). | Never confuse Asthma (GINA) and COPD (GOLD) inhaler rules on FNP exams: (1) In Asthma, NEVER prescribe a LABA without an ICS (FDA Black Box Warning for asthma-related death), and under current GINA guidelines, do not treat even mild Step 1 asthma with SABA alone—use as-needed low-dose ICS-Formoterol (Track 1) or take an ICS whenever SABA is taken (Track 2). (2) In COPD (irreversible airflow limitation: post-bronchodilator FEV_1/FVC < 0.70), long-acting bronchodilators (LABA + LAMA) are the backbone for Groups B and E, while ICS is NEVER used as monotherapy and is added (Triple Therapy: LABA + LAMA + ICS) primarily in Group E patients with blood eosinophils >= 300 cells/uL (or >= 100 cells/uL with recurrent exacerbations). | A) GINA Step 1 recommends as-needed SABA monotherapy, and LABA monotherapy (Salmeterol without an ICS) is safe first-line maintenance therapy in asthma; B) GINA eliminated SABA-only monotherapy for asthma because regular or frequent SABA use without an Inhaled Corticosteroid (ICS) downregulates beta-2 receptors, increases airway hyperresponsiveness, and increases severe exacerbations and death; GINA Track 1 (Preferred across Steps 1–5) uses low-dose ICS-Formoterol (e.g., Budesonide-Formoterol / Symbicort) as the reliever (as-needed only in Steps 1–2, and as daily Maintenance And Reliever Therapy [MART] in Steps 3–5); in GOLD COPD (post-bronchodilator FEV_1/FVC < 0.70): Group A (0–1 moderate exacerbations, low symptoms mMRC 0–1 / CAT < 10) -> single bronchodilator; Group B (0–1 moderate exacerbations, high symptoms mMRC >= 2 or CAT >= 10) -> LABA + LAMA; Group E (>= 2 moderate exacerbations or >= 1 hospitalization) -> LABA + LAMA (adding ICS for Triple Therapy LABA + LAMA + ICS if blood eosinophils >= 300 cells/uL) — Never confuse Asthma (GINA) and COPD (GOLD) inhaler rules on FNP exams: (1) In Asthma, NEVER prescribe a LABA without an ICS (FDA Black Box Warning for asthma-related death), and under current GINA guidelines, do not treat even mild Step 1 asthma with SABA alone—use as-needed low-dose ICS-Formoterol (Track 1) or take an ICS whenever SABA is taken (Track 2). (2) In COPD (irreversible airflow limitation: post-bronchodilator FEV_1/FVC < 0.70), long-acting bronchodilators (LABA + LAMA) are the backbone for Groups B and E, while ICS is NEVER used as monotherapy and is added (Triple Therapy: LABA + LAMA + ICS) primarily in Group E patients with blood eosinophils >= 300 cells/uL (or >= 100 cells/uL with recurrent exacerbations). ✓; C) GOLD COPD guidelines recommend inhaled corticosteroid (ICS) monotherapy as first-line treatment for all COPD patients regardless of eosinophil count; D) COPD is diagnosed when post-bronchodilator FEV_1/FVC is >= 0.80 and completely reversible |
| 10 | Contrast Diabetes Insipidus (DI) and Syndrome of Inappropriate Antidiuretic Hormone (SIADH) following pituitary/neurosurgery or small-cell lung cancer across Urine Output, Urine Specific Gravity / Osmolality, Serum Sodium (Na^+), and targeted pharmacotherapy (including the rate limit for correcting chronic hyponatremia). | Diabetes Insipidus (ADH deficiency or renal resistance — 'Dry Inside'): Massive dilute polyuria (> 250 mL/hr), LOW Urine Specific Gravity (< 1.005) and Urine Osmolality (< 200 mOsm/kg), HIGH Serum Sodium (Hypernatremia, Na^+ > 145 mEq/L) and Serum Osmolality (> 295 mOsm/kg); treated with hypotonic fluid replacement and Desmopressin (DDAVP) for Central DI. SIADH (excess ADH — 'Soaked Inside'): Oliguria with concentrated urine, HIGH Urine Specific Gravity (> 1.030) and Urine Osmolality, LOW Serum Sodium (Euvolemic/Hypervolemic Hyponatremia, Na^+ < 135 mEq/L) and low Serum Osmolality; treated with free water restriction, loop diuretics, Vaptans (Tolvaptan), and cautious 3% Hypertonic Saline for severe neurologic symptoms (seizures/coma)—correcting serum Na^+ by NO MORE THAN 8–10 mEq/L in 24 hours to prevent Osmotic Demyelination Syndrome (Central Pontine Myelinolysis) — Remember the mnemonic: DI = 'Dry Inside' (deficiency of ADH -> water pours out into the urine -> dilute urine with Specific Gravity < 1.005, while blood becomes concentrated with Hypernatremia Na^+ > 145; treat Central DI with DDAVP / Vasopressin). SIADH = 'Soaked Inside' (excess ADH -> kidneys retain pure free water -> concentrated urine with high Specific Gravity/Osmolality, while blood is diluted with Hyponatremia Na^+ < 135; correct Na^+ <= 8–10 mEq/L per 24 hours to prevent irreversible Osmotic Demyelination Syndrome / Central Pontine Myelinolysis). | Remember the mnemonic: DI = 'Dry Inside' (deficiency of ADH -> water pours out into the urine -> dilute urine with Specific Gravity < 1.005, while blood becomes concentrated with Hypernatremia Na^+ > 145; treat Central DI with DDAVP / Vasopressin). SIADH = 'Soaked Inside' (excess ADH -> kidneys retain pure free water -> concentrated urine with high Specific Gravity/Osmolality, while blood is diluted with Hyponatremia Na^+ < 135; correct Na^+ <= 8–10 mEq/L per 24 hours to prevent irreversible Osmotic Demyelination Syndrome / Central Pontine Myelinolysis). | A) In severe SIADH with Na^+ = 112 mEq/L, infuse 3% NaCl rapidly to normalize Na^+ to 140 mEq/L within 6 hours; B) Diabetes Insipidus (ADH deficiency or renal resistance — 'Dry Inside'): Massive dilute polyuria (> 250 mL/hr), LOW Urine Specific Gravity (< 1.005) and Urine Osmolality (< 200 mOsm/kg), HIGH Serum Sodium (Hypernatremia, Na^+ > 145 mEq/L) and Serum Osmolality (> 295 mOsm/kg); treated with hypotonic fluid replacement and Desmopressin (DDAVP) for Central DI. SIADH (excess ADH — 'Soaked Inside'): Oliguria with concentrated urine, HIGH Urine Specific Gravity (> 1.030) and Urine Osmolality, LOW Serum Sodium (Euvolemic/Hypervolemic Hyponatremia, Na^+ < 135 mEq/L) and low Serum Osmolality; treated with free water restriction, loop diuretics, Vaptans (Tolvaptan), and cautious 3% Hypertonic Saline for severe neurologic symptoms (seizures/coma)—correcting serum Na^+ by NO MORE THAN 8–10 mEq/L in 24 hours to prevent Osmotic Demyelination Syndrome (Central Pontine Myelinolysis) — Remember the mnemonic: DI = 'Dry Inside' (deficiency of ADH -> water pours out into the urine -> dilute urine with Specific Gravity < 1.005, while blood becomes concentrated with Hypernatremia Na^+ > 145; treat Central DI with DDAVP / Vasopressin). SIADH = 'Soaked Inside' (excess ADH -> kidneys retain pure free water -> concentrated urine with high Specific Gravity/Osmolality, while blood is diluted with Hyponatremia Na^+ < 135; correct Na^+ <= 8–10 mEq/L per 24 hours to prevent irreversible Osmotic Demyelination Syndrome / Central Pontine Myelinolysis). ✓; C) Diabetes Insipidus causes hyponatremia and high urine specific gravity (> 1.030); SIADH causes hypernatremia and dilute polyuria; D) Desmopressin (DDAVP) is the first-line treatment for SIADH |
| 11 | Under the ACC/AHA/HFSA Heart Failure Guidelines, what are the 4 foundational medication pillars ('Quadruple Therapy' GDMT) proven to reduce mortality in Heart Failure with Reduced Ejection Fraction (HFrEF, LVEF <= 40%), which 3 specific Beta-Blockers are evidence-based for HFrEF, and what mandatory washout rule applies when switching from an ACE Inhibitor to Sacubitril/Valsartan (Entresto)? | The 4 mortality-reducing HFrEF GDMT pillars are: (1) ARNI (Sacubitril/Valsartan — preferred) or ACEi/ARB, (2) Evidence-Based Beta-Blocker (ONLY Carvedilol, Metoprolol Succinate ER [Toprol-XL], or Bisoprolol), (3) Mineralocorticoid Receptor Antagonist (Spironolactone or Eplerenone), and (4) SGLT2 Inhibitor (Dapagliflozin or Empagliflozin — reduces mortality in HFrEF with or without diabetes); switching from an ACE Inhibitor to Sacubitril/Valsartan requires a mandatory 36-HOUR WASHOUT PERIOD to prevent life-threatening bradykinin-mediated angioedema (no washout needed when switching from an ARB) — High-yield FNP & CCRN pharmacology facts for HFrEF (LVEF <= 40%): (1) Quadruple GDMT (ARNI + Beta-Blocker + MRA + SGLT2i) reduces mortality by >60%; Loop Diuretics (Furosemide) are essential for volume congestion symptom relief but do NOT reduce mortality! (2) Only the '3 Bs/Cs' Beta-Blockers reduce HFrEF mortality: Bisoprolol, Carvedilol, and Metoprolol Succinate ER (NOT Tartrate, NOT Atenolol). (3) Because both ACE inhibitors and neprilysin inhibitors (Sacubitril) block bradykinin breakdown, a strict 36-hour washout window after the last dose of an ACEi is mandatory before starting Sacubitril/Valsartan. | High-yield FNP & CCRN pharmacology facts for HFrEF (LVEF <= 40%): (1) Quadruple GDMT (ARNI + Beta-Blocker + MRA + SGLT2i) reduces mortality by >60%; Loop Diuretics (Furosemide) are essential for volume congestion symptom relief but do NOT reduce mortality! (2) Only the '3 Bs/Cs' Beta-Blockers reduce HFrEF mortality: Bisoprolol, Carvedilol, and Metoprolol Succinate ER (NOT Tartrate, NOT Atenolol). (3) Because both ACE inhibitors and neprilysin inhibitors (Sacubitril) block bradykinin breakdown, a strict 36-hour washout window after the last dose of an ACEi is mandatory before starting Sacubitril/Valsartan. | A) The 4 mortality-reducing pillars are Furosemide (Lasix), Digoxin, Atenolol, and Amlodipine; no washout is needed between Lisinopril and Entresto; B) Metoprolol Tartrate (immediate-release) and Propranolol are the preferred mortality-reducing beta-blockers in HFrEF; C) Loop diuretics (Furosemide) reduce long-term mortality in HFrEF, whereas SGLT2 inhibitors are indicated only if HbA1c >= 7.0%; D) The 4 mortality-reducing HFrEF GDMT pillars are: (1) ARNI (Sacubitril/Valsartan — preferred) or ACEi/ARB, (2) Evidence-Based Beta-Blocker (ONLY Carvedilol, Metoprolol Succinate ER [Toprol-XL], or Bisoprolol), (3) Mineralocorticoid Receptor Antagonist (Spironolactone or Eplerenone), and (4) SGLT2 Inhibitor (Dapagliflozin or Empagliflozin — reduces mortality in HFrEF with or without diabetes); switching from an ACE Inhibitor to Sacubitril/Valsartan requires a mandatory 36-HOUR WASHOUT PERIOD to prevent life-threatening bradykinin-mediated angioedema (no washout needed when switching from an ARB) — High-yield FNP & CCRN pharmacology facts for HFrEF (LVEF <= 40%): (1) Quadruple GDMT (ARNI + Beta-Blocker + MRA + SGLT2i) reduces mortality by >60%; Loop Diuretics (Furosemide) are essential for volume congestion symptom relief but do NOT reduce mortality! (2) Only the '3 Bs/Cs' Beta-Blockers reduce HFrEF mortality: Bisoprolol, Carvedilol, and Metoprolol Succinate ER (NOT Tartrate, NOT Atenolol). (3) Because both ACE inhibitors and neprilysin inhibitors (Sacubitril) block bradykinin breakdown, a strict 36-hour washout window after the last dose of an ACEi is mandatory before starting Sacubitril/Valsartan. ✓ |
| 12 | In FE Electrical Engineering, a balanced three-phase industrial motor load draws 40 kW of real power (P) at a lagging power factor of cos(theta) = 0.80 from a 480 V (line-to-line RMS) 60 Hz supply. Calculate the Apparent Power (\|S\|), the Reactive Power (Q), the Line Current (I_L), and state how the power factor is corrected toward unity. | Apparent Power \|S\| = 50.0 kVA (P / PF = 40 kW / 0.80); Reactive Power Q = +30.0 kVAR (sqrt(50^2 - 40^2) = 50 × sin(36.87°) = 50 × 0.60, inductive); Line Current I_L = 60.14 A (\|S\| / (sqrt(3) × V_L) = 50,000 VA / (1.732 × 480 V)); power factor is corrected toward 1.0 by connecting a capacitor bank in PARALLEL with the inductive load to supply -30 kVAR of capacitive reactive power — From the AC Power Triangle (3-4-5 triangle for PF = 0.80 lagging): (1) Apparent Power \|S\| = P / cos(theta) = 40 kW / 0.80 = 50.0 kVA. (2) Inductive Reactive Power Q = \|S\| × sin(theta) = 50.0 × 0.60 = +30.0 kVAR. (3) From P_3phi = sqrt(3) × V_L × I_L × cos(theta) = \|S\|, Line Current I_L = 50,000 / (sqrt(3) × 480) = 50,000 / 831.38 = 60.14 A. (4) Connecting a 30 kVAR capacitor bank in parallel supplies Q_C = -30 kVAR locally, reducing net reactive power Q_net to 0, reducing \|S\| to 40 kVA, and lowering line current I_L to 48.11 A. | From the AC Power Triangle (3-4-5 triangle for PF = 0.80 lagging): (1) Apparent Power \|S\| = P / cos(theta) = 40 kW / 0.80 = 50.0 kVA. (2) Inductive Reactive Power Q = \|S\| × sin(theta) = 50.0 × 0.60 = +30.0 kVAR. (3) From P_3phi = sqrt(3) × V_L × I_L × cos(theta) = \|S\|, Line Current I_L = 50,000 / (sqrt(3) × 480) = 50,000 / 831.38 = 60.14 A. (4) Connecting a 30 kVAR capacitor bank in parallel supplies Q_C = -30 kVAR locally, reducing net reactive power Q_net to 0, reducing \|S\| to 40 kVA, and lowering line current I_L to 48.11 A. | A) Apparent Power \|S\| = 50.0 kVA (P / PF = 40 kW / 0.80); Reactive Power Q = +30.0 kVAR (sqrt(50^2 - 40^2) = 50 × sin(36.87°) = 50 × 0.60, inductive); Line Current I_L = 60.14 A (\|S\| / (sqrt(3) × V_L) = 50,000 VA / (1.732 × 480 V)); power factor is corrected toward 1.0 by connecting a capacitor bank in PARALLEL with the inductive load to supply -30 kVAR of capacitive reactive power — From the AC Power Triangle (3-4-5 triangle for PF = 0.80 lagging): (1) Apparent Power \|S\| = P / cos(theta) = 40 kW / 0.80 = 50.0 kVA. (2) Inductive Reactive Power Q = \|S\| × sin(theta) = 50.0 × 0.60 = +30.0 kVAR. (3) From P_3phi = sqrt(3) × V_L × I_L × cos(theta) = \|S\|, Line Current I_L = 50,000 / (sqrt(3) × 480) = 50,000 / 831.38 = 60.14 A. (4) Connecting a 30 kVAR capacitor bank in parallel supplies Q_C = -30 kVAR locally, reducing net reactive power Q_net to 0, reducing \|S\| to 40 kVA, and lowering line current I_L to 48.11 A. ✓; B) Apparent Power \|S\| = 32.0 kVA (40 × 0.80); Reactive Power Q = 24.0 kVAR; Line Current I_L = 104.17 A (50,000 / 480); corrected by adding inductors in series; C) Apparent Power \|S\| = 50.0 kVA; Reactive Power Q = 10.0 kVAR; Line Current I_L = 83.33 A; D) Apparent Power \|S\| = 50.0 kVA; Reactive Power Q = +30.0 kVAR; Line Current I_L = 34.72 A (dividing by 3 instead of sqrt(3)) |
| 13 | In FNP Hematology, how do you differentiate Iron Deficiency Anemia (IDA) from Beta-Thalassemia Trait (both Microcytic Anemias with MCV < 80 fL), and Vitamin B12 (Cobalamin) Deficiency from Folate (Vitamin B9) Deficiency (both Macrocytic Megaloblastic Anemias with MCV > 100 fL)? | Microcytic (MCV < 80 fL): Iron Deficiency Anemia has LOW Serum Ferritin (most specific test!), LOW Serum Iron, HIGH Total Iron-Binding Capacity (TIBC), LOW Transferrin Saturation, HIGH RDW (anisocytosis), and low RBC count (in an adult male or postmenopausal female, IDA mandates GI endoscopy/colonoscopy to rule out occult colorectal malignancy!); Beta-Thalassemia Trait has marked microcytosis (MCV often < 70 fL), NORMAL or ELEVATED RBC count (Mentzer Index = MCV/RBC < 13), NORMAL Ferritin/Iron/TIBC, NORMAL RDW, and elevated HbA2 on Hemoglobin Electrophoresis. Macrocytic (MCV > 100 fL): Vitamin B12 deficiency presents with neurologic deficits (peripheral neuropathy, paresthesias, ataxia/positive Romberg from dorsal column demyelination) and elevates BOTH Methylmalonic Acid (MMA) AND Homocysteine; Folate deficiency has NO neurologic symptoms and elevates Homocysteine ONLY (Normal MMA) — Master the two classic FNP anemia differentials: (1) IDA vs. Thalassemia Trait: IDA = Low Ferritin, High TIBC, High RDW, Mentzer Index (MCV/RBC) > 13. Thalassemia Trait = Normal Ferritin, Normal TIBC, Normal RDW, HIGH RBC count (Mentzer Index < 13), diagnosed definitively by Hemoglobin Electrophoresis (NEVER give iron supplementation to a Thalassemia patient unless coexisting iron deficiency is proven, as it causes iron overload!). (2) B12 vs. Folate: B12 deficiency = Neurologic signs + HIGH MMA + HIGH Homocysteine. Folate deficiency = NO neurologic signs + NORMAL MMA + HIGH Homocysteine. | Master the two classic FNP anemia differentials: (1) IDA vs. Thalassemia Trait: IDA = Low Ferritin, High TIBC, High RDW, Mentzer Index (MCV/RBC) > 13. Thalassemia Trait = Normal Ferritin, Normal TIBC, Normal RDW, HIGH RBC count (Mentzer Index < 13), diagnosed definitively by Hemoglobin Electrophoresis (NEVER give iron supplementation to a Thalassemia patient unless coexisting iron deficiency is proven, as it causes iron overload!). (2) B12 vs. Folate: B12 deficiency = Neurologic signs + HIGH MMA + HIGH Homocysteine. Folate deficiency = NO neurologic signs + NORMAL MMA + HIGH Homocysteine. | A) Folate deficiency causes elevated Methylmalonic Acid (MMA) and subacute combined degeneration of the spinal cord; B) Iron Deficiency Anemia has High Ferritin and Low TIBC, whereas Beta-Thalassemia Trait has Low Ferritin and High TIBC; C) Microcytic (MCV < 80 fL): Iron Deficiency Anemia has LOW Serum Ferritin (most specific test!), LOW Serum Iron, HIGH Total Iron-Binding Capacity (TIBC), LOW Transferrin Saturation, HIGH RDW (anisocytosis), and low RBC count (in an adult male or postmenopausal female, IDA mandates GI endoscopy/colonoscopy to rule out occult colorectal malignancy!); Beta-Thalassemia Trait has marked microcytosis (MCV often < 70 fL), NORMAL or ELEVATED RBC count (Mentzer Index = MCV/RBC < 13), NORMAL Ferritin/Iron/TIBC, NORMAL RDW, and elevated HbA2 on Hemoglobin Electrophoresis. Macrocytic (MCV > 100 fL): Vitamin B12 deficiency presents with neurologic deficits (peripheral neuropathy, paresthesias, ataxia/positive Romberg from dorsal column demyelination) and elevates BOTH Methylmalonic Acid (MMA) AND Homocysteine; Folate deficiency has NO neurologic symptoms and elevates Homocysteine ONLY (Normal MMA) — Master the two classic FNP anemia differentials: (1) IDA vs. Thalassemia Trait: IDA = Low Ferritin, High TIBC, High RDW, Mentzer Index (MCV/RBC) > 13. Thalassemia Trait = Normal Ferritin, Normal TIBC, Normal RDW, HIGH RBC count (Mentzer Index < 13), diagnosed definitively by Hemoglobin Electrophoresis (NEVER give iron supplementation to a Thalassemia patient unless coexisting iron deficiency is proven, as it causes iron overload!). (2) B12 vs. Folate: B12 deficiency = Neurologic signs + HIGH MMA + HIGH Homocysteine. Folate deficiency = NO neurologic signs + NORMAL MMA + HIGH Homocysteine. ✓; D) Beta-Thalassemia Trait should be treated with high-dose oral ferrous sulfate (325 mg TID) for 6 months |
| 14 | In FE Thermodynamics, an ideal Carnot heat engine operates between a high-temperature steam reservoir at T_H = 527°C and a low-temperature cooling reservoir at T_L = 27°C. What is the maximum possible thermal efficiency (eta_max) of this heat engine, and what is the power output of an adiabatic steam turbine (open steady-flow system) with mass flow rate m_dot = 10 kg/s, inlet enthalpy h_1 = 3,200 kJ/kg, and exit enthalpy h_2 = 2,400 kJ/kg (neglecting KE and PE changes)? | Carnot Thermal Efficiency eta_max = 62.5% (using absolute Kelvin temperatures: 1 - (27 + 273) / (527 + 273) = 1 - 300 K / 800 K = 500 / 800); Adiabatic Turbine Power Output W_dot = 8,000 kW or 8.0 MW (m_dot × (h_1 - h_2) = 10 kg/s × (3,200 - 2,400) kJ/kg) — (1) Always convert temperatures to absolute scale (Kelvin = °C + 273.15) before applying Second Law Carnot formulas: T_H = 527 + 273 = 800 K, T_L = 27 + 273 = 300 K, so eta_th,max = 1 - (T_L / T_H) = 1 - (300 / 800) = 0.625 (62.5%). (2) By the First Law for an open steady-flow control volume (Q_dot - W_dot = m_dot[(h_2 - h_1) + (V_2^2 - V_1^2)/2 + g(z_2 - z_1)]), an adiabatic turbine (Q_dot = 0, negligible KE/PE) produces shaft power W_dot_out = m_dot(h_1 - h_2) = 10 kg/s × (3,200 - 2,400) kJ/kg = 8,000 kJ/s = 8,000 kW (8.0 MW). | (1) Always convert temperatures to absolute scale (Kelvin = °C + 273.15) before applying Second Law Carnot formulas: T_H = 527 + 273 = 800 K, T_L = 27 + 273 = 300 K, so eta_th,max = 1 - (T_L / T_H) = 1 - (300 / 800) = 0.625 (62.5%). (2) By the First Law for an open steady-flow control volume (Q_dot - W_dot = m_dot[(h_2 - h_1) + (V_2^2 - V_1^2)/2 + g(z_2 - z_1)]), an adiabatic turbine (Q_dot = 0, negligible KE/PE) produces shaft power W_dot_out = m_dot(h_1 - h_2) = 10 kg/s × (3,200 - 2,400) kJ/kg = 8,000 kJ/s = 8,000 kW (8.0 MW). | A) Carnot Thermal Efficiency eta_max = 62.5% (using absolute Kelvin temperatures: 1 - (27 + 273) / (527 + 273) = 1 - 300 K / 800 K = 500 / 800); Adiabatic Turbine Power Output W_dot = 8,000 kW or 8.0 MW (m_dot × (h_1 - h_2) = 10 kg/s × (3,200 - 2,400) kJ/kg) — (1) Always convert temperatures to absolute scale (Kelvin = °C + 273.15) before applying Second Law Carnot formulas: T_H = 527 + 273 = 800 K, T_L = 27 + 273 = 300 K, so eta_th,max = 1 - (T_L / T_H) = 1 - (300 / 800) = 0.625 (62.5%). (2) By the First Law for an open steady-flow control volume (Q_dot - W_dot = m_dot[(h_2 - h_1) + (V_2^2 - V_1^2)/2 + g(z_2 - z_1)]), an adiabatic turbine (Q_dot = 0, negligible KE/PE) produces shaft power W_dot_out = m_dot(h_1 - h_2) = 10 kg/s × (3,200 - 2,400) kJ/kg = 8,000 kJ/s = 8,000 kW (8.0 MW). ✓; B) Carnot Thermal Efficiency eta_max = 37.5% (300 K / 800 K); Turbine Power Output = 56,000 kW; C) Carnot Thermal Efficiency eta_max = 94.9% (using Celsius directly: 1 - 27 / 527); Turbine Power Output = 800 kW; D) Carnot Thermal Efficiency eta_max = 62.5%; Turbine Power Output = 0 kW because Q_dot = 0 in an adiabatic process |
| 15 | In FE Fluid Mechanics, water (kinematic viscosity nu = 1.0 × 10^-6 m^2/s, density rho = 1,000 kg/m^3) flows at an average velocity V = 2.0 m/s through a horizontal circular pipe of inside diameter D = 0.10 m and length L = 100 m with Darcy friction factor f = 0.020. Calculate the Reynolds Number (Re), identify the flow regime, and calculate the major head loss (h_f) and pressure drop (Delta_P) using the Darcy-Weisbach equation (take g = 9.81 m/s^2). | Re = 200,000 (V × D / nu = 2.0 × 0.10 / 1.0 × 10^-6 > 4,000 -> Fully Turbulent flow); Darcy-Weisbach Head Loss h_f = 4.08 m (f × (L/D) × (V^2 / 2g) = 0.020 × (100 / 0.10) × (2.0^2 / (2 × 9.81))); Horizontal Pressure Drop Delta_P = 40.0 kPa (rho × g × h_f = 1,000 × 9.81 × 4.077 = 40,000 Pa) — (1) Reynolds Number Re = V × D / nu = (2.0 m/s × 0.10 m) / (1.0 × 10^-6 m^2/s) = 2.0 × 10^5 = 200,000 (since Re > 4,000, the flow is fully turbulent; laminar is Re < 2,100). (2) By the Darcy-Weisbach equation, h_f = f(L / D)(V^2 / 2g) = 0.020 × (100 / 0.10) × (4.0 / 19.62) = 20 × 0.20387 = 4.077 m. (3) By the Extended Bernoulli equation for a horizontal constant-diameter pipe (V_1 = V_2, z_1 = z_2), Delta_P = gamma × h_f = rho × g × h_f = 0.020 × (1,000) × (0.5 × 1,000 × 2.0^2) = 40,000 Pa = 40.0 kPa. | (1) Reynolds Number Re = V × D / nu = (2.0 m/s × 0.10 m) / (1.0 × 10^-6 m^2/s) = 2.0 × 10^5 = 200,000 (since Re > 4,000, the flow is fully turbulent; laminar is Re < 2,100). (2) By the Darcy-Weisbach equation, h_f = f(L / D)(V^2 / 2g) = 0.020 × (100 / 0.10) × (4.0 / 19.62) = 20 × 0.20387 = 4.077 m. (3) By the Extended Bernoulli equation for a horizontal constant-diameter pipe (V_1 = V_2, z_1 = z_2), Delta_P = gamma × h_f = rho × g × h_f = 0.020 × (1,000) × (0.5 × 1,000 × 2.0^2) = 40,000 Pa = 40.0 kPa. | A) Re = 20,000; Head Loss h_f = 0.41 m; Pressure Drop Delta_P = 4.0 kPa; B) Re = 200,000 (V × D / nu = 2.0 × 0.10 / 1.0 × 10^-6 > 4,000 -> Fully Turbulent flow); Darcy-Weisbach Head Loss h_f = 4.08 m (f × (L/D) × (V^2 / 2g) = 0.020 × (100 / 0.10) × (2.0^2 / (2 × 9.81))); Horizontal Pressure Drop Delta_P = 40.0 kPa (rho × g × h_f = 1,000 × 9.81 × 4.077 = 40,000 Pa) — (1) Reynolds Number Re = V × D / nu = (2.0 m/s × 0.10 m) / (1.0 × 10^-6 m^2/s) = 2.0 × 10^5 = 200,000 (since Re > 4,000, the flow is fully turbulent; laminar is Re < 2,100). (2) By the Darcy-Weisbach equation, h_f = f(L / D)(V^2 / 2g) = 0.020 × (100 / 0.10) × (4.0 / 19.62) = 20 × 0.20387 = 4.077 m. (3) By the Extended Bernoulli equation for a horizontal constant-diameter pipe (V_1 = V_2, z_1 = z_2), Delta_P = gamma × h_f = rho × g × h_f = 0.020 × (1,000) × (0.5 × 1,000 × 2.0^2) = 40,000 Pa = 40.0 kPa. ✓; C) Re = 2,000 (Laminar flow); Head Loss h_f = 2.04 m; Pressure Drop Delta_P = 20.0 kPa; D) Re = 200,000 (Turbulent flow); Head Loss h_f = 8.15 m (omitting the factor of 2 in 2g); Pressure Drop Delta_P = 80.0 kPa |
| 16 | A 70-kg (Predicted Body Weight) patient in septic shock develops severe Acute Respiratory Distress Syndrome (ARDS: acute bilateral pulmonary infiltrates, PAWP = 10 mmHg, PaO_2 = 55 mmHg on FiO_2 = 0.80 and PEEP = 10 cmH_2O). Under the ARDSNet lung-protective ventilation protocol and Berlin Criteria, what is the patient's PaO_2/FiO_2 ratio and ARDS severity, what are the target Tidal Volume (V_T) and maximum Plateau Pressure (P_plat), and what intervention reduces mortality when PaO_2/FiO_2 < 150 mmHg? | PaO_2/FiO_2 ratio = 68.75 mmHg (55 / 0.80 <= 100 mmHg -> Severe ARDS); ARDSNet targets low Tidal Volume of 4–8 mL/kg (target 6 mL/kg = 420 mL) of Predicted Body Weight (PBW, based on height and sex), Plateau Pressure (P_plat) <= 30 cmH_2O (to prevent alveolar barotrauma/volutrauma, accepting permissive hypercapnia), higher PEEP to prevent atelectrauma, and early PRONE POSITIONING for >= 16 hours/day (which significantly reduces mortality in moderate-to-severe ARDS with P/F < 150) — Berlin ARDS severity by PaO_2/FiO_2 (on PEEP >= 5 cmH_2O): Mild = 201–300 mmHg; Moderate = 101–200 mmHg; Severe = <= 100 mmHg (here 55 / 0.80 = 68.75 mmHg = Severe ARDS). ARDSNet lung-protective ventilation uses: (1) Low V_T = 6 mL/kg (range 4–8 mL/kg) of Predicted Body Weight (PBW), (2) Plateau Pressure P_plat <= 30 cmH_2O (and Driving Pressure = P_plat - PEEP < 15 cmH_2O), (3) Permissive hypercapnia (pH >= 7.20–7.25, unless contraindicated by elevated ICP!), and (4) Prone positioning >= 16 hrs/day when P/F < 150 (PROSEVA trial). | Berlin ARDS severity by PaO_2/FiO_2 (on PEEP >= 5 cmH_2O): Mild = 201–300 mmHg; Moderate = 101–200 mmHg; Severe = <= 100 mmHg (here 55 / 0.80 = 68.75 mmHg = Severe ARDS). ARDSNet lung-protective ventilation uses: (1) Low V_T = 6 mL/kg (range 4–8 mL/kg) of Predicted Body Weight (PBW), (2) Plateau Pressure P_plat <= 30 cmH_2O (and Driving Pressure = P_plat - PEEP < 15 cmH_2O), (3) Permissive hypercapnia (pH >= 7.20–7.25, unless contraindicated by elevated ICP!), and (4) Prone positioning >= 16 hrs/day when P/F < 150 (PROSEVA trial). | A) Place the patient in reverse Trendelenburg and use zero PEEP (ZEEP) to prevent pneumothorax; B) PaO_2/FiO_2 ratio = 44 mmHg (55 × 0.80 -> Mild ARDS); target Tidal Volume of 10–12 mL/kg of actual body weight (840 mL) to normalize PaCO_2 to 35 mmHg and Plateau Pressure <= 50 cmH_2O; C) Administer high-dose IV Furosemide because bilateral infiltrates indicate left ventricular fluid overload (PAWP > 18 mmHg); D) PaO_2/FiO_2 ratio = 68.75 mmHg (55 / 0.80 <= 100 mmHg -> Severe ARDS); ARDSNet targets low Tidal Volume of 4–8 mL/kg (target 6 mL/kg = 420 mL) of Predicted Body Weight (PBW, based on height and sex), Plateau Pressure (P_plat) <= 30 cmH_2O (to prevent alveolar barotrauma/volutrauma, accepting permissive hypercapnia), higher PEEP to prevent atelectrauma, and early PRONE POSITIONING for >= 16 hours/day (which significantly reduces mortality in moderate-to-severe ARDS with P/F < 150) — Berlin ARDS severity by PaO_2/FiO_2 (on PEEP >= 5 cmH_2O): Mild = 201–300 mmHg; Moderate = 101–200 mmHg; Severe = <= 100 mmHg (here 55 / 0.80 = 68.75 mmHg = Severe ARDS). ARDSNet lung-protective ventilation uses: (1) Low V_T = 6 mL/kg (range 4–8 mL/kg) of Predicted Body Weight (PBW), (2) Plateau Pressure P_plat <= 30 cmH_2O (and Driving Pressure = P_plat - PEEP < 15 cmH_2O), (3) Permissive hypercapnia (pH >= 7.20–7.25, unless contraindicated by elevated ICP!), and (4) Prone positioning >= 16 hrs/day when P/F < 150 (PROSEVA trial). ✓ |
| 17 | Under the CDC US Medical Eligibility Criteria for Contraceptive Use (US MEC), which patient conditions are Category 4 (Absolute Contraindications) to Estrogen-containing Combined Hormonal Contraceptives (CHCs: pills, patch, vaginal ring), and what are the key prenatal gestational milestones at 12, 20, 24–28, and 36–37 weeks? | CDC US MEC Category 4 (NO Estrogen): (1) Migraine WITH Aura at any age (ischemic stroke risk), (2) Smoking >= 15 cigarettes/day at age >= 35 years (any smoking at age >= 35 is Cat 3/4), (3) Current or history of DVT/PE or known thrombogenic mutation, (4) Current or history of Breast Cancer, (5) Uncontrolled Hypertension (SBP >= 160 or DBP >= 100 mmHg) or HTN with vascular disease, (6) < 21 days postpartum, and (7) Severe decompensated cirrhosis or liver tumors; Prenatal Milestones: Fundal height at symphysis pubis at 12 weeks and at umbilicus at 20 weeks; Gestational Diabetes screening + RhoGAM (300 mcg IM for Rh-negative unsensitized mothers) at 24–28 weeks; Group B Streptococcus (GBS) vaginal-rectal swab at 36 0/7 to 37 6/7 weeks — (1) On FNP exams, anytime a vignette describes a woman of ANY age experiencing visual scintillations, fortification spectra, or sensory symptoms before a headache (Migraine WITH Aura) or a smoker aged >= 35, Estrogen-containing contraceptives (COCs, patch, ring) are strictly CONTRAINDICATED (US MEC Category 4—switch to progestin-only pill, Nexplanon, or IUD). (2) Prenatal milestones: 10–12 wks fetal heart tones by Doppler + fundus at symphysis pubis; 20 wks fundus at umbilicus + anatomy ultrasound (fundal height in cm = weeks gestation ± 2 cm from 20–36 wks); 24–28 wks GDM screen + 28-wk RhoGAM; 36–37 wks GBS screen. | (1) On FNP exams, anytime a vignette describes a woman of ANY age experiencing visual scintillations, fortification spectra, or sensory symptoms before a headache (Migraine WITH Aura) or a smoker aged >= 35, Estrogen-containing contraceptives (COCs, patch, ring) are strictly CONTRAINDICATED (US MEC Category 4—switch to progestin-only pill, Nexplanon, or IUD). (2) Prenatal milestones: 10–12 wks fetal heart tones by Doppler + fundus at symphysis pubis; 20 wks fundus at umbilicus + anatomy ultrasound (fundal height in cm = weeks gestation ± 2 cm from 20–36 wks); 24–28 wks GDM screen + 28-wk RhoGAM; 36–37 wks GBS screen. | A) Migraine without aura in a 24-year-old non-smoker and family history of breast cancer are Category 4 absolute contraindications to Combined Oral Contraceptives; B) Fundal height reaches the umbilicus at 12 weeks and the xiphoid process at 20 weeks; GBS swab is performed at 20 weeks; C) Progestin-only pills, Levonorgestrel IUD, and Nexplanon implant are Category 4 contraindicated in patients with Migraine with Aura; D) CDC US MEC Category 4 (NO Estrogen): (1) Migraine WITH Aura at any age (ischemic stroke risk), (2) Smoking >= 15 cigarettes/day at age >= 35 years (any smoking at age >= 35 is Cat 3/4), (3) Current or history of DVT/PE or known thrombogenic mutation, (4) Current or history of Breast Cancer, (5) Uncontrolled Hypertension (SBP >= 160 or DBP >= 100 mmHg) or HTN with vascular disease, (6) < 21 days postpartum, and (7) Severe decompensated cirrhosis or liver tumors; Prenatal Milestones: Fundal height at symphysis pubis at 12 weeks and at umbilicus at 20 weeks; Gestational Diabetes screening + RhoGAM (300 mcg IM for Rh-negative unsensitized mothers) at 24–28 weeks; Group B Streptococcus (GBS) vaginal-rectal swab at 36 0/7 to 37 6/7 weeks — (1) On FNP exams, anytime a vignette describes a woman of ANY age experiencing visual scintillations, fortification spectra, or sensory symptoms before a headache (Migraine WITH Aura) or a smoker aged >= 35, Estrogen-containing contraceptives (COCs, patch, ring) are strictly CONTRAINDICATED (US MEC Category 4—switch to progestin-only pill, Nexplanon, or IUD). (2) Prenatal milestones: 10–12 wks fetal heart tones by Doppler + fundus at symphysis pubis; 20 wks fundus at umbilicus + anatomy ultrasound (fundal height in cm = weeks gestation ± 2 cm from 20–36 wks); 24–28 wks GDM screen + 28-wk RhoGAM; 36–37 wks GBS screen. ✓ |
| 18 | In FNP Orthopedics and Neurology, match the physical examination special test to the correct pathology: (1) Lachman Test, (2) McMurray & Thessaly Tests, (3) Empty Can (Jobe) & Drop Arm Tests, (4) Neer & Hawkins-Kennedy Tests, (5) Phalen & Tinel Signs, and (6) Finkelstein Test. | (1) Lachman Test -> Anterior Cruciate Ligament (ACL) tear (most sensitive clinical test, superior to Anterior Drawer); (2) McMurray & Thessaly Tests -> Meniscal tear (joint-line clicking/pain on rotation); (3) Empty Can (Jobe) & Drop Arm Tests -> Supraspinatus / Rotator Cuff tear; (4) Neer & Hawkins-Kennedy Tests -> Subacromial Shoulder Impingement; (5) Phalen & Tinel Signs -> Carpal Tunnel Syndrome (Median nerve compression, affecting thumb, index, middle, and radial half of ring finger; thenar atrophy); (6) Finkelstein Test -> De Quervain Tenosynovitis (abductor pollicis longus and extensor pollicis brevis tendons at radial styloid) — High-yield FNP musculoskeletal exam pairings: Knee: Lachman = ACL (#1 sensitivity), Posterior Drawer = PCL, Valgus stress = MCL, Varus stress = LCL, McMurray/Thessaly = Meniscus. Shoulder: Empty Can (Jobe) & Drop Arm = Supraspinatus/Rotator Cuff tear; Neer & Hawkins = Subacromial Impingement; Apprehension/Relocation = Glenohumeral instability. Wrist/Hand: Phalen/Tinel = Carpal Tunnel (Median nerve: digits 1, 2, 3, radial 1/2 of 4); Finkelstein (grasping thumb in fist and ulnar-deviating wrist) = De Quervain tenosynovitis. | High-yield FNP musculoskeletal exam pairings: Knee: Lachman = ACL (#1 sensitivity), Posterior Drawer = PCL, Valgus stress = MCL, Varus stress = LCL, McMurray/Thessaly = Meniscus. Shoulder: Empty Can (Jobe) & Drop Arm = Supraspinatus/Rotator Cuff tear; Neer & Hawkins = Subacromial Impingement; Apprehension/Relocation = Glenohumeral instability. Wrist/Hand: Phalen/Tinel = Carpal Tunnel (Median nerve: digits 1, 2, 3, radial 1/2 of 4); Finkelstein (grasping thumb in fist and ulnar-deviating wrist) = De Quervain tenosynovitis. | A) (1) Lachman Test -> Anterior Cruciate Ligament (ACL) tear (most sensitive clinical test, superior to Anterior Drawer); (2) McMurray & Thessaly Tests -> Meniscal tear (joint-line clicking/pain on rotation); (3) Empty Can (Jobe) & Drop Arm Tests -> Supraspinatus / Rotator Cuff tear; (4) Neer & Hawkins-Kennedy Tests -> Subacromial Shoulder Impingement; (5) Phalen & Tinel Signs -> Carpal Tunnel Syndrome (Median nerve compression, affecting thumb, index, middle, and radial half of ring finger; thenar atrophy); (6) Finkelstein Test -> De Quervain Tenosynovitis (abductor pollicis longus and extensor pollicis brevis tendons at radial styloid) — High-yield FNP musculoskeletal exam pairings: Knee: Lachman = ACL (#1 sensitivity), Posterior Drawer = PCL, Valgus stress = MCL, Varus stress = LCL, McMurray/Thessaly = Meniscus. Shoulder: Empty Can (Jobe) & Drop Arm = Supraspinatus/Rotator Cuff tear; Neer & Hawkins = Subacromial Impingement; Apprehension/Relocation = Glenohumeral instability. Wrist/Hand: Phalen/Tinel = Carpal Tunnel (Median nerve: digits 1, 2, 3, radial 1/2 of 4); Finkelstein (grasping thumb in fist and ulnar-deviating wrist) = De Quervain tenosynovitis. ✓; B) Lachman Test diagnoses Meniscal tear; McMurray Test diagnoses ACL tear; Finkelstein Test diagnoses Ulnar nerve entrapment; C) Carpal Tunnel Syndrome compresses the Ulnar nerve and causes numbness in the 5th (little) finger and hypothenar eminence; D) Drop Arm Test diagnoses Adhesive Capsulitis (Frozen Shoulder), and Hawkins-Kennedy Test diagnoses Bicipital Tendonitis |
| 19 | On the AACN CCRN exam, what are the normal physiological reference ranges for a Pulmonary Artery Catheter (Swan-Ganz): Central Venous Pressure (CVP), Pulmonary Artery Pressure (PAP), Pulmonary Artery Wedge Pressure (PAWP / PCWP), Cardiac Index (CI), and Systemic Vascular Resistance (SVR), and what is the exact formula for SVR? | CVP (Right Ventricular Preload) = 2–6 mmHg; PAP = 15–30 mmHg systolic / 8–15 mmHg diastolic (Mean 10–20 mmHg); PAWP/PCWP (Left Ventricular Preload) = 6–12 mmHg; Cardiac Output (CO) = 4–8 L/min and Cardiac Index (CI) = 2.5–4.0 L/min/m^2; SVR (Left Ventricular Afterload) = 800–1,200 dyn·s·cm^-5, calculated as SVR = 80 × (MAP - CVP) / CO — Memorize these exact Swan-Ganz numbers and equations for CCRN: CVP (RAP) = 2–6 mmHg (RV preload); RVP = 15–30 / 2–8 mmHg; PAP = 15–30 / 8–15 mmHg; PAWP (PCWP) = 6–12 mmHg (LV preload); CO = 4–8 L/min; CI = 2.5–4.0 L/min/m^2; SvO_2 = 60%–80%; SVR = 80 × (MAP - CVP) / CO = 800–1,200 dyn·s·cm^-5 (LV afterload); and PVR = 80 × (MPAP - PAWP) / CO = 100–250 dyn·s·cm^-5 (RV afterload). In testing an ICU patient with BP 90/60 (MAP = 70), CVP = 4, and CO = 3.3 L/min, SVR = 80 × (70 - 4) / 3.3 = 1,600 dyn·s·cm^-5 (elevated vasoconstriction). | Memorize these exact Swan-Ganz numbers and equations for CCRN: CVP (RAP) = 2–6 mmHg (RV preload); RVP = 15–30 / 2–8 mmHg; PAP = 15–30 / 8–15 mmHg; PAWP (PCWP) = 6–12 mmHg (LV preload); CO = 4–8 L/min; CI = 2.5–4.0 L/min/m^2; SvO_2 = 60%–80%; SVR = 80 × (MAP - CVP) / CO = 800–1,200 dyn·s·cm^-5 (LV afterload); and PVR = 80 × (MPAP - PAWP) / CO = 100–250 dyn·s·cm^-5 (RV afterload). In testing an ICU patient with BP 90/60 (MAP = 70), CVP = 4, and CO = 3.3 L/min, SVR = 80 × (70 - 4) / 3.3 = 1,600 dyn·s·cm^-5 (elevated vasoconstriction). | A) CVP = 6–12 mmHg; PAWP = 2–6 mmHg; SVR = (MAP + CVP) × 80 / CI; B) CVP = 8–15 mmHg; PAP = 100–120 / 60–80 mmHg; PAWP = 15–25 mmHg; SVR = 100–250 dyn·s·cm^-5, calculated as 80 × (MPAP - PAWP) / CO; C) CVP = 0–2 mmHg; PAP = 30–50 / 15–25 mmHg; PAWP = 18–24 mmHg; SVR = 1,500–2,500 dyn·s·cm^-5; D) CVP (Right Ventricular Preload) = 2–6 mmHg; PAP = 15–30 mmHg systolic / 8–15 mmHg diastolic (Mean 10–20 mmHg); PAWP/PCWP (Left Ventricular Preload) = 6–12 mmHg; Cardiac Output (CO) = 4–8 L/min and Cardiac Index (CI) = 2.5–4.0 L/min/m^2; SVR (Left Ventricular Afterload) = 800–1,200 dyn·s·cm^-5, calculated as SVR = 80 × (MAP - CVP) / CO — Memorize these exact Swan-Ganz numbers and equations for CCRN: CVP (RAP) = 2–6 mmHg (RV preload); RVP = 15–30 / 2–8 mmHg; PAP = 15–30 / 8–15 mmHg; PAWP (PCWP) = 6–12 mmHg (LV preload); CO = 4–8 L/min; CI = 2.5–4.0 L/min/m^2; SvO_2 = 60%–80%; SVR = 80 × (MAP - CVP) / CO = 800–1,200 dyn·s·cm^-5 (LV afterload); and PVR = 80 × (MPAP - PAWP) / CO = 100–250 dyn·s·cm^-5 (RV afterload). In testing an ICU patient with BP 90/60 (MAP = 70), CVP = 4, and CO = 3.3 L/min, SVR = 80 × (70 - 4) / 3.3 = 1,600 dyn·s·cm^-5 (elevated vasoconstriction). ✓ |
| 20 | Summarize the current US Preventive Services Task Force (USPSTF) Grade A/B screening guidelines tested on the FNP boards for Colorectal Cancer, Lung Cancer, Breast Cancer, Cervical Cancer, Abdominal Aortic Aneurysm (AAA), and Osteoporosis. | Colorectal Cancer: Ages 45–75 (colonoscopy q10 yrs, FIT annually, sDNA-FIT q1–3 yrs); Lung Cancer: Annual Low-Dose CT (LDCT) for adults aged 50–80 with a >= 20 pack-year smoking history who currently smoke or quit within the past 15 years; Breast Cancer: Biennial screening mammography for women aged 40–74; Cervical Cancer: Ages 21–29 Pap cytology alone every 3 years (NO HPV testing under age 30!), Ages 30–65 primary hrHPV testing every 5 years, co-testing (Pap + hrHPV) every 5 years, or Pap alone every 3 years; AAA: 1-time abdominal ultrasound in MEN aged 65–75 who have EVER smoked (>= 100 lifetime cigarettes); Osteoporosis: DEXA scan in all women aged >= 65 (or younger postmenopausal women with equivalent fracture risk; T-score <= -2.5 diagnoses Osteoporosis, -1.0 to -2.4 Osteopenia) — Note the three major USPSTF age/threshold updates tested heavily on AANP and ANCC: (1) Colorectal Cancer screening start age lowered from 50 to 45 (ages 45–75; selective 76–85). (2) Lung Cancer annual LDCT lowered from age 55 / 30 pack-years to age 50–80 / >= 20 pack-years (currently smoking or quit within 15 years). (3) Breast Cancer biennial mammography lowered from start age 50 to age 40 (ages 40–74). And never order cervical cancer screening before age 21 regardless of age at sexual debut! | Note the three major USPSTF age/threshold updates tested heavily on AANP and ANCC: (1) Colorectal Cancer screening start age lowered from 50 to 45 (ages 45–75; selective 76–85). (2) Lung Cancer annual LDCT lowered from age 55 / 30 pack-years to age 50–80 / >= 20 pack-years (currently smoking or quit within 15 years). (3) Breast Cancer biennial mammography lowered from start age 50 to age 40 (ages 40–74). And never order cervical cancer screening before age 21 regardless of age at sexual debut! | A) Colorectal cancer screening starts at age 50; Lung cancer LDCT starts at age 55 with a 30 pack-year history; Cervical Pap smears begin at age 18 or onset of sexual activity; B) All men and women aged 65–75 should receive an annual abdominal ultrasound for AAA regardless of smoking history; C) Colorectal Cancer: Ages 45–75 (colonoscopy q10 yrs, FIT annually, sDNA-FIT q1–3 yrs); Lung Cancer: Annual Low-Dose CT (LDCT) for adults aged 50–80 with a >= 20 pack-year smoking history who currently smoke or quit within the past 15 years; Breast Cancer: Biennial screening mammography for women aged 40–74; Cervical Cancer: Ages 21–29 Pap cytology alone every 3 years (NO HPV testing under age 30!), Ages 30–65 primary hrHPV testing every 5 years, co-testing (Pap + hrHPV) every 5 years, or Pap alone every 3 years; AAA: 1-time abdominal ultrasound in MEN aged 65–75 who have EVER smoked (>= 100 lifetime cigarettes); Osteoporosis: DEXA scan in all women aged >= 65 (or younger postmenopausal women with equivalent fracture risk; T-score <= -2.5 diagnoses Osteoporosis, -1.0 to -2.4 Osteopenia) — Note the three major USPSTF age/threshold updates tested heavily on AANP and ANCC: (1) Colorectal Cancer screening start age lowered from 50 to 45 (ages 45–75; selective 76–85). (2) Lung Cancer annual LDCT lowered from age 55 / 30 pack-years to age 50–80 / >= 20 pack-years (currently smoking or quit within 15 years). (3) Breast Cancer biennial mammography lowered from start age 50 to age 40 (ages 40–74). And never order cervical cancer screening before age 21 regardless of age at sexual debut! ✓; D) Routine PSA screening is USPSTF Grade A for all men starting at age 40 |
| 21 | Under the ACC/AHA Hypertension Guidelines tested on the FNP boards (AANP / ANCC), what are the diagnostic blood pressure thresholds for Normal, Elevated, Stage 1, and Stage 2 Hypertension, and how does first-line antihypertensive drug selection differ for (1) a Black adult without CKD/HF, (2) a patient with Diabetic Nephropathy (albuminuria), and (3) a pregnant woman? | Normal: < 120 AND < 80 mmHg; Elevated: 120–129 AND < 80 mmHg; Stage 1 HTN: 130–139 OR 80–89 mmHg; Stage 2 HTN: >= 140 OR >= 90 mmHg; First-line tailored therapy: (1) Black adults without HF or CKD -> Thiazide diuretic (Chlorthalidone) or Dihydropyridine Calcium Channel Blocker (Amlodipine); (2) Diabetes with Albuminuria (UACR >= 30 mg/g) or Proteinuric CKD -> ACE Inhibitor (Lisinopril) or ARB (Losartan) (never combine ACEi + ARB!); (3) Pregnancy -> Labetalol, Extended-Release Nifedipine, or Methyldopa (ACEi, ARBs, and Direct Renin Inhibitors are strictly CONTRAINDICATED due to fetal renal teratogenicity) — On the AANP/ANCC FNP exams, know the 2017 ACC/AHA blood pressure stages (<120/<80 Normal; 120–129/<80 Elevated; 130–139 or 80–89 Stage 1; >=140 or >=90 Stage 2; initiate 2 first-line agents of different classes if Stage 2 or >20/10 mmHg above goal) and population rules: (1) Black patients (without CKD/HF): CCB or Thiazide first-line (low-renin physiology + 3–4x higher rate of ACEi angioedema). (2) Proteinuric CKD / Diabetic Albuminuria: ACEi or ARB (dilates efferent arteriole, reducing intraglomerular pressure; never combine ACEi + ARB!). (3) Pregnancy: Labetalol, Nifedipine ER, or Methyldopa (stop ACEi/ARB/Statins immediately upon conception). | On the AANP/ANCC FNP exams, know the 2017 ACC/AHA blood pressure stages (<120/<80 Normal; 120–129/<80 Elevated; 130–139 or 80–89 Stage 1; >=140 or >=90 Stage 2; initiate 2 first-line agents of different classes if Stage 2 or >20/10 mmHg above goal) and population rules: (1) Black patients (without CKD/HF): CCB or Thiazide first-line (low-renin physiology + 3–4x higher rate of ACEi angioedema). (2) Proteinuric CKD / Diabetic Albuminuria: ACEi or ARB (dilates efferent arteriole, reducing intraglomerular pressure; never combine ACEi + ARB!). (3) Pregnancy: Labetalol, Nifedipine ER, or Methyldopa (stop ACEi/ARB/Statins immediately upon conception). | A) Normal: < 120 AND < 80 mmHg; Elevated: 120–129 AND < 80 mmHg; Stage 1 HTN: 130–139 OR 80–89 mmHg; Stage 2 HTN: >= 140 OR >= 90 mmHg; First-line tailored therapy: (1) Black adults without HF or CKD -> Thiazide diuretic (Chlorthalidone) or Dihydropyridine Calcium Channel Blocker (Amlodipine); (2) Diabetes with Albuminuria (UACR >= 30 mg/g) or Proteinuric CKD -> ACE Inhibitor (Lisinopril) or ARB (Losartan) (never combine ACEi + ARB!); (3) Pregnancy -> Labetalol, Extended-Release Nifedipine, or Methyldopa (ACEi, ARBs, and Direct Renin Inhibitors are strictly CONTRAINDICATED due to fetal renal teratogenicity) — On the AANP/ANCC FNP exams, know the 2017 ACC/AHA blood pressure stages (<120/<80 Normal; 120–129/<80 Elevated; 130–139 or 80–89 Stage 1; >=140 or >=90 Stage 2; initiate 2 first-line agents of different classes if Stage 2 or >20/10 mmHg above goal) and population rules: (1) Black patients (without CKD/HF): CCB or Thiazide first-line (low-renin physiology + 3–4x higher rate of ACEi angioedema). (2) Proteinuric CKD / Diabetic Albuminuria: ACEi or ARB (dilates efferent arteriole, reducing intraglomerular pressure; never combine ACEi + ARB!). (3) Pregnancy: Labetalol, Nifedipine ER, or Methyldopa (stop ACEi/ARB/Statins immediately upon conception). ✓; B) Combining Lisinopril (ACEi) plus Losartan (ARB) is recommended to double renal protection in diabetic nephropathy; C) Stage 1 HTN starts at 140/90 mmHg and Stage 2 HTN starts at 160/100 mmHg; Lisinopril is first-line in pregnancy; D) Black adults without CKD should receive an ACE Inhibitor monotherapy as preferred first-line therapy |
| 22 | Under the NCEES Model Rules of Professional Conduct (Engineering Ethics), what is a licensed Professional Engineer's paramount duty, when may a licensee sign and seal engineering plans, and what must a licensee do if their professional engineering judgment is overruled under circumstances where public safety is endangered? | Licensees must hold PARAMOUNT the safety, health, and welfare of the public; they may sign and seal ONLY plans/specifications prepared by them or under their direct supervisory control ('responsible charge') within their specific area of competence; if their engineering judgment is overruled in a way that endangers public safety, health, or welfare, they MUST inform their employer or client AND notify the appropriate regulatory authority — Three bedrock rules of NCEES Engineering Ethics: (1) Public safety, health, and welfare are ALWAYS paramount above client confidentiality or employer loyalty. (2) A PE may affix their seal only to technical documents prepared personally or under their direct 'responsible charge' and only in subjects where they are qualified by education/experience ('plan stamping' work done outside their supervision or competence is a major violation). (3) If overruled on a matter endangering public safety, the engineer must notify the client/employer AND report the hazard to the appropriate public authority. | Three bedrock rules of NCEES Engineering Ethics: (1) Public safety, health, and welfare are ALWAYS paramount above client confidentiality or employer loyalty. (2) A PE may affix their seal only to technical documents prepared personally or under their direct 'responsible charge' and only in subjects where they are qualified by education/experience ('plan stamping' work done outside their supervision or competence is a major violation). (3) If overruled on a matter endangering public safety, the engineer must notify the client/employer AND report the hazard to the appropriate public authority. | A) A licensee's primary duty is loyalty and confidentiality to the client paying the fee, which prohibits reporting unsafe conditions to outside building officials; B) A licensed Civil PE may sign and seal complex high-voltage electrical substation designs prepared by an unlicensed contractor if the Civil PE reviews the cover sheet; C) A licensee may accept undisclosed referral commissions from equipment vendors specified in a public works design if the equipment meets minimum code standards; D) Licensees must hold PARAMOUNT the safety, health, and welfare of the public; they may sign and seal ONLY plans/specifications prepared by them or under their direct supervisory control ('responsible charge') within their specific area of competence; if their engineering judgment is overruled in a way that endangers public safety, health, or welfare, they MUST inform their employer or client AND notify the appropriate regulatory authority — Three bedrock rules of NCEES Engineering Ethics: (1) Public safety, health, and welfare are ALWAYS paramount above client confidentiality or employer loyalty. (2) A PE may affix their seal only to technical documents prepared personally or under their direct 'responsible charge' and only in subjects where they are qualified by education/experience ('plan stamping' work done outside their supervision or competence is a major violation). (3) If overruled on a matter endangering public safety, the engineer must notify the client/employer AND report the hazard to the appropriate public authority. ✓ |
| 23 | Under the American Diabetes Association (ADA) Standards of Care in Diabetes, what are the 4 diagnostic criteria for Diabetes Mellitus (and Prediabetes ranges), which two antihyperglycemic drug classes provide proven cardiorenal protection for patients with ASCVD, Heart Failure, or CKD, and what are their classic contraindications and adverse effects? | Diabetes Diagnosis: HbA1c >= 6.5%, Fasting Plasma Glucose (FPG) >= 126 mg/dL, 2-hr 75-g OGTT >= 200 mg/dL, or Random Glucose >= 200 mg/dL with classic symptoms (Prediabetes: HbA1c 5.7%–6.4%, FPG 100–125 mg/dL, 2-hr OGTT 140–199 mg/dL); Cardiorenal Protection (independent of baseline A1c or Metformin): (1) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin) reduce HF hospitalization and CKD progression (adverse effects: genital mycotic yeast infections, volume depletion, euglycemic DKA); (2) GLP-1 Receptor Agonists (Semaglutide, Liraglutide) reduce MACE in ASCVD and drive weight loss (CONTRAINDICATED in personal or family history of Medullary Thyroid Carcinoma [MTC] or Multiple Endocrine Neoplasia syndrome type 2 [MEN 2], and history of pancreatitis); Metformin is contraindicated when eGFR < 30 mL/min/1.73 m^2 (lactic acidosis risk) and requires monitoring for Vitamin B12 deficiency — High-yield ADA Pharmacology rules on FNP boards: (1) SGLT2 inhibitors ('-flozins') are #1 for Heart Failure (HFrEF/HFpEF) and Diabetic CKD (watch for genital candidiasis, Fournier's gangrene, and euglycemic DKA). (2) GLP-1 RAs ('-glutides') are #1 for ASCVD and weight loss, and carry an FDA Black Box Warning for thyroid C-cell tumors (contraindicated in personal/family history of Medullary Thyroid Carcinoma [MTC] or MEN 2—NOT ordinary hypothyroidism!). (3) Thiazolidinediones (Pioglitazone) cause fluid retention and are CONTRAINDICATED in NYHA Class III–IV Heart Failure (and increase bladder cancer and distal bone fracture risk). | High-yield ADA Pharmacology rules on FNP boards: (1) SGLT2 inhibitors ('-flozins') are #1 for Heart Failure (HFrEF/HFpEF) and Diabetic CKD (watch for genital candidiasis, Fournier's gangrene, and euglycemic DKA). (2) GLP-1 RAs ('-glutides') are #1 for ASCVD and weight loss, and carry an FDA Black Box Warning for thyroid C-cell tumors (contraindicated in personal/family history of Medullary Thyroid Carcinoma [MTC] or MEN 2—NOT ordinary hypothyroidism!). (3) Thiazolidinediones (Pioglitazone) cause fluid retention and are CONTRAINDICATED in NYHA Class III–IV Heart Failure (and increase bladder cancer and distal bone fracture risk). | A) Pioglitazone (TZD) reduces heart failure hospitalizations, and GLP-1 Receptor Agonists are contraindicated in patients with hypothyroidism (Hashimoto's thyroiditis); B) Diabetes Diagnosis: HbA1c >= 6.5%, Fasting Plasma Glucose (FPG) >= 126 mg/dL, 2-hr 75-g OGTT >= 200 mg/dL, or Random Glucose >= 200 mg/dL with classic symptoms (Prediabetes: HbA1c 5.7%–6.4%, FPG 100–125 mg/dL, 2-hr OGTT 140–199 mg/dL); Cardiorenal Protection (independent of baseline A1c or Metformin): (1) SGLT2 Inhibitors (Empagliflozin, Dapagliflozin) reduce HF hospitalization and CKD progression (adverse effects: genital mycotic yeast infections, volume depletion, euglycemic DKA); (2) GLP-1 Receptor Agonists (Semaglutide, Liraglutide) reduce MACE in ASCVD and drive weight loss (CONTRAINDICATED in personal or family history of Medullary Thyroid Carcinoma [MTC] or Multiple Endocrine Neoplasia syndrome type 2 [MEN 2], and history of pancreatitis); Metformin is contraindicated when eGFR < 30 mL/min/1.73 m^2 (lactic acidosis risk) and requires monitoring for Vitamin B12 deficiency — High-yield ADA Pharmacology rules on FNP boards: (1) SGLT2 inhibitors ('-flozins') are #1 for Heart Failure (HFrEF/HFpEF) and Diabetic CKD (watch for genital candidiasis, Fournier's gangrene, and euglycemic DKA). (2) GLP-1 RAs ('-glutides') are #1 for ASCVD and weight loss, and carry an FDA Black Box Warning for thyroid C-cell tumors (contraindicated in personal/family history of Medullary Thyroid Carcinoma [MTC] or MEN 2—NOT ordinary hypothyroidism!). (3) Thiazolidinediones (Pioglitazone) cause fluid retention and are CONTRAINDICATED in NYHA Class III–IV Heart Failure (and increase bladder cancer and distal bone fracture risk). ✓; C) Diabetes is diagnosed at FPG >= 110 mg/dL or HbA1c >= 6.0%; Sulfonylureas (Glipizide) and Thiazolidinediones (Pioglitazone) are first-line for Heart Failure; D) Metformin can be safely continued at full dose when eGFR is 15 mL/min/1.73 m^2 and causes weight gain and severe hypoglycemia |
| 24 | A patient presents to the ICU with crushing chest pain and ST-segment elevation in Leads II, III, and aVF on the 12-lead ECG. Blood pressure is 82/54 mmHg, heart rate is 52 bpm (sinus bradycardia), lungs are clear to auscultation, and marked jugular venous distension (JVD) is present. Which coronary artery is occluded, what confirmatory ECG lead must be obtained, and what is the priority hemodynamic treatment vs. absolute contraindication? | Inferior wall STEMI (Leads II, III, aVF) caused by Right Coronary Artery (RCA) occlusion complicated by Right Ventricular (RV) Infarction (classic triad: hypotension, JVD, and CLEAR lung fields); confirm immediately with a right-sided 12-lead ECG looking for ST elevation in Lead V4R; because the ischemic RV is preload-dependent, treat hypotension with isotonic IV fluid boluses (0.9% NaCl) before inotropes, and STRICTLY AVOID preload-reducing agents (Nitroglycerin, Morphine, and Loop Diuretics) — Inferior STEMI (Leads II, III, aVF -> RCA) is complicated by Right Ventricular Infarction in ~40% of cases. Always recognize the classic RV Infarction triad: Hypotension + Elevated JVP (high CVP) + CLEAR lungs (low/normal PAWP). Confirm with right-sided precordial Lead V4R. Because the stunned RV relies entirely on passive preload to fill the left heart, giving Nitroglycerin, Morphine, or Diuretics collapses venous return and precipitates fatal cardiovascular collapse—give IV normal saline boluses instead! | Inferior STEMI (Leads II, III, aVF -> RCA) is complicated by Right Ventricular Infarction in ~40% of cases. Always recognize the classic RV Infarction triad: Hypotension + Elevated JVP (high CVP) + CLEAR lungs (low/normal PAWP). Confirm with right-sided precordial Lead V4R. Because the stunned RV relies entirely on passive preload to fill the left heart, giving Nitroglycerin, Morphine, or Diuretics collapses venous return and precipitates fatal cardiovascular collapse—give IV normal saline boluses instead! | A) Anterior wall STEMI caused by Left Anterior Descending (LAD) occlusion; administer sublingual Nitroglycerin and IV Furosemide (Lasix) immediately to reduce JVD; B) Inferior wall STEMI (Leads II, III, aVF) caused by Right Coronary Artery (RCA) occlusion complicated by Right Ventricular (RV) Infarction (classic triad: hypotension, JVD, and CLEAR lung fields); confirm immediately with a right-sided 12-lead ECG looking for ST elevation in Lead V4R; because the ischemic RV is preload-dependent, treat hypotension with isotonic IV fluid boluses (0.9% NaCl) before inotropes, and STRICTLY AVOID preload-reducing agents (Nitroglycerin, Morphine, and Loop Diuretics) — Inferior STEMI (Leads II, III, aVF -> RCA) is complicated by Right Ventricular Infarction in ~40% of cases. Always recognize the classic RV Infarction triad: Hypotension + Elevated JVP (high CVP) + CLEAR lungs (low/normal PAWP). Confirm with right-sided precordial Lead V4R. Because the stunned RV relies entirely on passive preload to fill the left heart, giving Nitroglycerin, Morphine, or Diuretics collapses venous return and precipitates fatal cardiovascular collapse—give IV normal saline boluses instead! ✓; C) Lateral wall STEMI caused by Left Circumflex (LCx) occlusion; confirm with posterior leads V7–V9 and restrict all IV fluids; D) Posterior STEMI; administer high-dose IV Metoprolol and Nitroprusside |
| 25 | Under the Surviving Sepsis Campaign guidelines tested on the CCRN exam, what are the components of the Hour-1 Bundle, the fluid resuscitation dose and fluid of choice, the target Mean Arterial Pressure (MAP), and the first-line and second-line vasopressors for Septic Shock? | Hour-1 Bundle: (1) Measure serum lactate (remeasure if > 2 mmol/L), (2) Obtain blood cultures BEFORE giving antibiotics, (3) Administer broad-spectrum IV antibiotics within 1 hour, (4) Administer 30 mL/kg of balanced IV crystalloid (Lactated Ringer's or Plasma-Lyte preferred over 0.9% Normal Saline to avoid hyperchloremic acidosis) for hypotension or lactate >= 4 mmol/L, and (5) Start vasopressors if hypotensive during/after fluids to maintain MAP >= 65 mmHg; First-line vasopressor is NOREPINEPHRINE (Levophed), Second-line add-on is VASOPRESSIN (0.03 units/min), and DOBUTAMINE (or Epinephrine) is added if persistent hypoperfusion is accompanied by myocardial dysfunction — In Septic Shock (Sepsis with persistent hypotension requiring vasopressors to maintain MAP >= 65 mmHg AND serum lactate > 2 mmol/L despite adequate 30 mL/kg balanced crystalloid resuscitation): Norepinephrine (potent alpha-1 vasoconstrictor with modest beta-1 activity) is the undisputed first-line vasopressor. Rather than escalating Norepinephrine to toxic doses, fixed-dose Vasopressin (up to 0.03 units/min) is added second-line. Dopamine is avoided due to tachyarrhythmias. | In Septic Shock (Sepsis with persistent hypotension requiring vasopressors to maintain MAP >= 65 mmHg AND serum lactate > 2 mmol/L despite adequate 30 mL/kg balanced crystalloid resuscitation): Norepinephrine (potent alpha-1 vasoconstrictor with modest beta-1 activity) is the undisputed first-line vasopressor. Rather than escalating Norepinephrine to toxic doses, fixed-dose Vasopressin (up to 0.03 units/min) is added second-line. Dopamine is avoided due to tachyarrhythmias. | A) Administer 10 mL/kg of 5% Dextrose in Water (D5W), target MAP >= 85 mmHg, and use Dopamine or Phenylephrine as the first-line vasopressor; B) Delay broad-spectrum antibiotics until 48-hour blood culture sensitivities return, and use IV Albumin as first-line resuscitation fluid; C) Hour-1 Bundle: (1) Measure serum lactate (remeasure if > 2 mmol/L), (2) Obtain blood cultures BEFORE giving antibiotics, (3) Administer broad-spectrum IV antibiotics within 1 hour, (4) Administer 30 mL/kg of balanced IV crystalloid (Lactated Ringer's or Plasma-Lyte preferred over 0.9% Normal Saline to avoid hyperchloremic acidosis) for hypotension or lactate >= 4 mmol/L, and (5) Start vasopressors if hypotensive during/after fluids to maintain MAP >= 65 mmHg; First-line vasopressor is NOREPINEPHRINE (Levophed), Second-line add-on is VASOPRESSIN (0.03 units/min), and DOBUTAMINE (or Epinephrine) is added if persistent hypoperfusion is accompanied by myocardial dysfunction — In Septic Shock (Sepsis with persistent hypotension requiring vasopressors to maintain MAP >= 65 mmHg AND serum lactate > 2 mmol/L despite adequate 30 mL/kg balanced crystalloid resuscitation): Norepinephrine (potent alpha-1 vasoconstrictor with modest beta-1 activity) is the undisputed first-line vasopressor. Rather than escalating Norepinephrine to toxic doses, fixed-dose Vasopressin (up to 0.03 units/min) is added second-line. Dopamine is avoided due to tachyarrhythmias. ✓; D) Use Dobutamine as the sole first-line agent to treat profound vasodilation in warm septic shock |
| 26 | On the CCRN exam, when caring for a patient in cardiogenic shock supported by an Intra-Aortic Balloon Pump (IABP), when does the balloon inflate and deflate in the cardiac cycle, what are the physiological goals of each phase, and which timing error is the most dangerous? | The IABP inflates at the DICROTIC NOTCH of the arterial pressure waveform (onset of diastole / aortic valve closure) to augment diastolic coronary artery perfusion pressure and O_2 supply; it deflates JUST PRIOR TO SYSTOLE (R wave on ECG / just before aortic valve opening) to create a vacuum effect that decreases Left Ventricular Afterload and myocardial O_2 demand; EARLY INFLATION (before aortic valve closure) is the most dangerous timing error because it forces premature closure of the aortic valve, traps blood in the LV, increases LV wall stress/afterload, and worsens aortic regurgitation — IABP counterpulsation rules: (1) Catheter tip sits in the descending thoracic aorta 2 cm distal to the left subclavian artery and above the renal arteries (if the catheter migrates upward and occludes the left subclavian artery, the LEFT radial pulse and left arm perfusion are lost; if it migrates downward, urine output drops from renal artery occlusion!). (2) Inflate at Dicrotic Notch (diastole -> increases coronary perfusion); Deflate just before Systole/R-wave (systole -> decreases LV afterload). (3) Early Inflation (before dicrotic notch) and Late Deflation (after aortic valve opens) both dangerously increase LV afterload. | IABP counterpulsation rules: (1) Catheter tip sits in the descending thoracic aorta 2 cm distal to the left subclavian artery and above the renal arteries (if the catheter migrates upward and occludes the left subclavian artery, the LEFT radial pulse and left arm perfusion are lost; if it migrates downward, urine output drops from renal artery occlusion!). (2) Inflate at Dicrotic Notch (diastole -> increases coronary perfusion); Deflate just before Systole/R-wave (systole -> decreases LV afterload). (3) Early Inflation (before dicrotic notch) and Late Deflation (after aortic valve opens) both dangerously increase LV afterload. | A) The tip of the IABP catheter is positioned in the ascending aorta proximal to the aortic arch, and loss of the left radial pulse is a normal expected finding; B) The IABP inflates during ventricular systole (R wave) to push blood forward to the brain and deflates at the dicrotic notch during diastole; C) The IABP inflates at the DICROTIC NOTCH of the arterial pressure waveform (onset of diastole / aortic valve closure) to augment diastolic coronary artery perfusion pressure and O_2 supply; it deflates JUST PRIOR TO SYSTOLE (R wave on ECG / just before aortic valve opening) to create a vacuum effect that decreases Left Ventricular Afterload and myocardial O_2 demand; EARLY INFLATION (before aortic valve closure) is the most dangerous timing error because it forces premature closure of the aortic valve, traps blood in the LV, increases LV wall stress/afterload, and worsens aortic regurgitation — IABP counterpulsation rules: (1) Catheter tip sits in the descending thoracic aorta 2 cm distal to the left subclavian artery and above the renal arteries (if the catheter migrates upward and occludes the left subclavian artery, the LEFT radial pulse and left arm perfusion are lost; if it migrates downward, urine output drops from renal artery occlusion!). (2) Inflate at Dicrotic Notch (diastole -> increases coronary perfusion); Deflate just before Systole/R-wave (systole -> decreases LV afterload). (3) Early Inflation (before dicrotic notch) and Late Deflation (after aortic valve opens) both dangerously increase LV afterload. ✓; D) Late inflation increases LV afterload and forces premature closure of the mitral valve |
| 27 | A patient presents to the ED in Diabetic Ketoacidosis (DKA) with blood glucose = 580 mg/dL, arterial pH = 7.14, HCO_3^- = 9 mEq/L, Na^+ = 132 mEq/L, Cl^- = 95 mEq/L, and serum Potassium (K^+) = 3.1 mEq/L. Calculate the Anion Gap, and state the exact sequence of fluid, potassium, and insulin management (including when to add Dextrose to the IV fluids). | Anion Gap = 28 mEq/L (132 - (95 + 9) = 28, severe high-anion-gap metabolic acidosis); Priority Sequence: (1) Begin aggressive isotonic IV fluid resuscitation FIRST (0.9% NaCl at 15–20 mL/kg/hr), (2) Because serum K^+ is 3.1 mEq/L (< 3.3 mEq/L), HOLD IV INSULIN and administer IV Potassium (20–40 mEq/hr) first until K^+ >= 3.3 mEq/L (since insulin drives K^+ into cells and would precipitate fatal hypokalemic cardiac arrest!), (3) Once K^+ >= 3.3 mEq/L, start continuous IV Regular Insulin (0.1 units/kg/hr) with K^+ supplementation (if K^+ is 3.3–5.2 mEq/L), and (4) When blood glucose reaches 200 mg/dL in DKA, ADD D5W (e.g., D5 0.45% NaCl) while CONTINUING the IV insulin infusion until the Anion Gap closes (<= 12 mEq/L) — Three life-saving DKA rules tested on CCRN and FNP boards: (1) Isotonic fluid resuscitation FIRST. (2) Check serum K^+ BEFORE starting insulin: if K^+ < 3.3 mEq/L, HOLD insulin and replace K^+ first; if K^+ is 3.3–5.2 mEq/L, add 20–30 mEq K^+/L of IV fluid and start insulin; if K^+ > 5.2 mEq/L, start insulin without K^+ and recheck K^+ every 2 hours. (3) Blood glucose normalizes HOURS before ketoacidosis resolves—when glucose drops to 200 mg/dL in DKA (250–300 mg/dL in HHS), NEVER turn off the insulin drip before the Anion Gap closes! Instead, add Dextrose (D5 0.45% NaCl) to prevent hypoglycemia/cerebral edema while continuing IV insulin to clear ketones and close the Anion Gap. | Three life-saving DKA rules tested on CCRN and FNP boards: (1) Isotonic fluid resuscitation FIRST. (2) Check serum K^+ BEFORE starting insulin: if K^+ < 3.3 mEq/L, HOLD insulin and replace K^+ first; if K^+ is 3.3–5.2 mEq/L, add 20–30 mEq K^+/L of IV fluid and start insulin; if K^+ > 5.2 mEq/L, start insulin without K^+ and recheck K^+ every 2 hours. (3) Blood glucose normalizes HOURS before ketoacidosis resolves—when glucose drops to 200 mg/dL in DKA (250–300 mg/dL in HHS), NEVER turn off the insulin drip before the Anion Gap closes! Instead, add Dextrose (D5 0.45% NaCl) to prevent hypoglycemia/cerebral edema while continuing IV insulin to clear ketones and close the Anion Gap. | A) Start IV Regular Insulin bolus and infusion immediately before checking or replacing potassium, and discontinue the insulin infusion as soon as blood glucose reaches 200 mg/dL; B) Administer routine IV Sodium Bicarbonate because pH is 7.14, and give subcutaneous NPH insulin; C) Anion Gap = 28 mEq/L (132 - (95 + 9) = 28, severe high-anion-gap metabolic acidosis); Priority Sequence: (1) Begin aggressive isotonic IV fluid resuscitation FIRST (0.9% NaCl at 15–20 mL/kg/hr), (2) Because serum K^+ is 3.1 mEq/L (< 3.3 mEq/L), HOLD IV INSULIN and administer IV Potassium (20–40 mEq/hr) first until K^+ >= 3.3 mEq/L (since insulin drives K^+ into cells and would precipitate fatal hypokalemic cardiac arrest!), (3) Once K^+ >= 3.3 mEq/L, start continuous IV Regular Insulin (0.1 units/kg/hr) with K^+ supplementation (if K^+ is 3.3–5.2 mEq/L), and (4) When blood glucose reaches 200 mg/dL in DKA, ADD D5W (e.g., D5 0.45% NaCl) while CONTINUING the IV insulin infusion until the Anion Gap closes (<= 12 mEq/L) — Three life-saving DKA rules tested on CCRN and FNP boards: (1) Isotonic fluid resuscitation FIRST. (2) Check serum K^+ BEFORE starting insulin: if K^+ < 3.3 mEq/L, HOLD insulin and replace K^+ first; if K^+ is 3.3–5.2 mEq/L, add 20–30 mEq K^+/L of IV fluid and start insulin; if K^+ > 5.2 mEq/L, start insulin without K^+ and recheck K^+ every 2 hours. (3) Blood glucose normalizes HOURS before ketoacidosis resolves—when glucose drops to 200 mg/dL in DKA (250–300 mg/dL in HHS), NEVER turn off the insulin drip before the Anion Gap closes! Instead, add Dextrose (D5 0.45% NaCl) to prevent hypoglycemia/cerebral edema while continuing IV insulin to clear ketones and close the Anion Gap. ✓; D) Start 0.45% NaCl with D5W immediately on admission when blood glucose is 580 mg/dL |
| 28 | A patient with end-stage renal disease (ESRD) who missed two hemodialysis sessions presents to the ICU with severe muscle weakness, serum Potassium (K^+) = 7.4 mEq/L, and a 12-lead ECG showing tall peaked T waves, flattened P waves, PR prolongation, and a widened QRS complex (0.16 sec). What is the exact three-step emergency physiological sequence and medication protocol for treating life-threatening Hyperkalemia? | Step 1 — Stabilize the cardiac myocyte membrane IMMEDIATELY (antagonizes membrane excitability within 1–3 minutes without changing serum K^+): administer IV Calcium Gluconate (or IV Calcium Chloride via central line) FIRST whenever ECG changes (beyond isolated peaked T waves) or K^+ > 6.5 mEq/L are present; Step 2 — Shift K^+ intracellularly (via Na+/K+-ATPase pump within 15–30 minutes): administer IV Regular Insulin (10 units) + IV Dextrose (D50W 25–50 g to prevent hypoglycemia), plus high-dose nebulized Albuterol (10–20 mg) and IV Sodium Bicarbonate (if metabolic acidosis is present); Step 3 — Remove K^+ from the body: Hemodialysis (most definitive for ESRD!), Loop Diuretics (Furosemide if renal function intact), and GI Potassium Binders (Patiromer or Sodium Zirconium Cyclosilicate [Lokelma]) — Emergency Hyperkalemia sequence ('C BIG K Drop'): (1) PROTECT THE HEART FIRST: IV Calcium Gluconate (10 mL of 10% over 2–3 min; stabilizes resting membrane potential threshold in 1–3 min, lasts 30–60 min, does NOT lower serum K^+; note exception: avoid IV calcium in Digoxin toxicity due to classic 'stone heart' concern—use Digoxin Immune Fab [Digibind] instead!). (2) SHIFT K^+ INTO CELLS: IV Regular Insulin 10 units + D50W (lowers K^+ by 0.5–1.2 mEq/L in 15–30 min) + high-dose inhaled Albuterol. (3) EXCRETE K^+ FROM BODY: Hemodialysis, Furosemide, or modern GI binders (Lokelma / Patiromer). | Emergency Hyperkalemia sequence ('C BIG K Drop'): (1) PROTECT THE HEART FIRST: IV Calcium Gluconate (10 mL of 10% over 2–3 min; stabilizes resting membrane potential threshold in 1–3 min, lasts 30–60 min, does NOT lower serum K^+; note exception: avoid IV calcium in Digoxin toxicity due to classic 'stone heart' concern—use Digoxin Immune Fab [Digibind] instead!). (2) SHIFT K^+ INTO CELLS: IV Regular Insulin 10 units + D50W (lowers K^+ by 0.5–1.2 mEq/L in 15–30 min) + high-dose inhaled Albuterol. (3) EXCRETE K^+ FROM BODY: Hemodialysis, Furosemide, or modern GI binders (Lokelma / Patiromer). | A) IV Calcium Gluconate rapidly lowers serum potassium by 2.0 mEq/L within 5 minutes by driving potassium into skeletal muscle cells; B) Administer oral Sodium Polystyrene Sulfonate (Kayexalate) first, followed 1 hour later by subcutaneous insulin, and avoid IV Calcium unless the patient is in asystole; C) In a patient taking Digoxin who presents with Digoxin toxicity and hyperkalemia, IV Calcium Chloride is the safest first-line agent; D) Step 1 — Stabilize the cardiac myocyte membrane IMMEDIATELY (antagonizes membrane excitability within 1–3 minutes without changing serum K^+): administer IV Calcium Gluconate (or IV Calcium Chloride via central line) FIRST whenever ECG changes (beyond isolated peaked T waves) or K^+ > 6.5 mEq/L are present; Step 2 — Shift K^+ intracellularly (via Na+/K+-ATPase pump within 15–30 minutes): administer IV Regular Insulin (10 units) + IV Dextrose (D50W 25–50 g to prevent hypoglycemia), plus high-dose nebulized Albuterol (10–20 mg) and IV Sodium Bicarbonate (if metabolic acidosis is present); Step 3 — Remove K^+ from the body: Hemodialysis (most definitive for ESRD!), Loop Diuretics (Furosemide if renal function intact), and GI Potassium Binders (Patiromer or Sodium Zirconium Cyclosilicate [Lokelma]) — Emergency Hyperkalemia sequence ('C BIG K Drop'): (1) PROTECT THE HEART FIRST: IV Calcium Gluconate (10 mL of 10% over 2–3 min; stabilizes resting membrane potential threshold in 1–3 min, lasts 30–60 min, does NOT lower serum K^+; note exception: avoid IV calcium in Digoxin toxicity due to classic 'stone heart' concern—use Digoxin Immune Fab [Digibind] instead!). (2) SHIFT K^+ INTO CELLS: IV Regular Insulin 10 units + D50W (lowers K^+ by 0.5–1.2 mEq/L in 15–30 min) + high-dose inhaled Albuterol. (3) EXCRETE K^+ FROM BODY: Hemodialysis, Furosemide, or modern GI binders (Lokelma / Patiromer). ✓ |
| 29 | In FE Engineering Economics, a municipality is evaluating a new water treatment pump that has an initial capital cost of $250,000, annual operating and maintenance (O&M) costs of $30,000 per year, and a salvage value of $40,000 at the end of its 10-year useful life. Using a MARR (interest rate i) of 8.0% per year (where (P/A, 8%, 10) = 6.7101 and (P/F, 8%, 10) = 0.4632), what is the Present Worth (PW) of the pump's net costs, and how is Capitalized Cost (CC) defined for an infinite horizon? | Present Worth of Costs = -$432,775 (-$250,000 - $30,000(6.7101) + $40,000(0.4632) = -$250,000 - $201,303 + $18,528); for a perpetual (infinite-life) asset such as a dam or bridge, Capitalized Cost CC = P_0 + (A / i) — Using standard NCEES factor notation: PW = -P_0 - A(P/A, 8%, 10) + S(P/F, 8%, 10) = -$250,000 - $30,000(6.7101) + $40,000(0.4632) = -$250,000 - $201,303 + $18,528 = -$432,775. For perpetual projects (n -> infinity), the Present Worth of an infinite uniform series A is A / i, so Capitalized Cost CC = Initial Cost P_0 + (Equivalent Annual Cost A / i). | Using standard NCEES factor notation: PW = -P_0 - A(P/A, 8%, 10) + S(P/F, 8%, 10) = -$250,000 - $30,000(6.7101) + $40,000(0.4632) = -$250,000 - $201,303 + $18,528 = -$432,775. For perpetual projects (n -> infinity), the Present Worth of an infinite uniform series A is A / i, so Capitalized Cost CC = Initial Cost P_0 + (Equivalent Annual Cost A / i). | A) Present Worth of Costs = -$469,831 (subtracting salvage value instead of adding it); Capitalized Cost CC = A × i; B) Present Worth of Costs = -$432,775 (-$250,000 - $30,000(6.7101) + $40,000(0.4632) = -$250,000 - $201,303 + $18,528); for a perpetual (infinite-life) asset such as a dam or bridge, Capitalized Cost CC = P_0 + (A / i) — Using standard NCEES factor notation: PW = -P_0 - A(P/A, 8%, 10) + S(P/F, 8%, 10) = -$250,000 - $30,000(6.7101) + $40,000(0.4632) = -$250,000 - $201,303 + $18,528 = -$432,775. For perpetual projects (n -> infinity), the Present Worth of an infinite uniform series A is A / i, so Capitalized Cost CC = Initial Cost P_0 + (Equivalent Annual Cost A / i). ✓; C) Present Worth of Costs = -$451,303 (ignoring the salvage value); Capitalized Cost CC = P_0 × i; D) Present Worth of Costs = -$510,000 (undiscounted sum of cash flows) |
| 30 | A patient with a severe Traumatic Brain Injury (TBI) has an arterial blood pressure of 110/65 mmHg and an Intracranial Pressure (ICP) via external ventricular drain (EVD) of 24 mmHg. Calculate the Mean Arterial Pressure (MAP) and Cerebral Perfusion Pressure (CPP), identify the components of Cushing's Triad, and state the target CPP and osmotherapy limits. | MAP = 80 mmHg ((110 + 2 × 65) / 3); CPP = 56 mmHg (MAP - ICP = 80 - 24, which is critically below the 60–70 mmHg Brain Trauma Foundation target, while ICP > 20–22 mmHg is elevated); Cushing's Triad of impending brainstem herniation consists of (1) Widening pulse pressure (systolic hypertension), (2) Reflex Bradycardia, and (3) Irregular respirations (Cheyne-Stokes); treat elevated ICP with HOB at 30° neutral midline neck, CSF drainage via EVD, and IV Hypertonic Saline (3%) or Mannitol (holding Mannitol if Serum Osmolality > 320 mOsm/kg or Osmolar Gap > 10–15) — (1) MAP = [SBP + 2(DBP)] / 3 = (110 + 130) / 3 = 80 mmHg. (2) CPP = MAP - ICP = 80 - 24 = 56 mmHg (normal ICP is 5–15 mmHg; treat ICP > 20–22 mmHg and maintain CPP between 60 and 70 mmHg). (3) Cushing's Triad (late sign of brainstem compression/herniation) is the exact OPPOSITE of hypovolemic shock: Systolic Hypertension with Widening Pulse Pressure + Bradycardia + Irregular Respirations. (4) Notice that CO_2 is a potent cerebral vasodilator: hypercapnia spikes ICP, whereas extreme prophylactic hyperventilation (PaCO_2 < 25 mmHg) causes severe cerebral vasoconstriction and brain ischemia (keep PaCO_2 35–40 mmHg, using brief target 30–35 mmHg only as a temporary bridge during acute herniation). | (1) MAP = [SBP + 2(DBP)] / 3 = (110 + 130) / 3 = 80 mmHg. (2) CPP = MAP - ICP = 80 - 24 = 56 mmHg (normal ICP is 5–15 mmHg; treat ICP > 20–22 mmHg and maintain CPP between 60 and 70 mmHg). (3) Cushing's Triad (late sign of brainstem compression/herniation) is the exact OPPOSITE of hypovolemic shock: Systolic Hypertension with Widening Pulse Pressure + Bradycardia + Irregular Respirations. (4) Notice that CO_2 is a potent cerebral vasodilator: hypercapnia spikes ICP, whereas extreme prophylactic hyperventilation (PaCO_2 < 25 mmHg) causes severe cerebral vasoconstriction and brain ischemia (keep PaCO_2 35–40 mmHg, using brief target 30–35 mmHg only as a temporary bridge during acute herniation). | A) MAP = 87.5 mmHg; CPP = 104 mmHg (MAP + ICP); Cushing's Triad consists of hypotension, tachycardia, and tachypnea (which is shock, the exact opposite of Cushing's Triad!); B) Hyperventilate the patient prophylactically to a target PaCO_2 of 20 mmHg for 72 hours to cause cerebral vasodilation; C) MAP = 80 mmHg ((110 + 2 × 65) / 3); CPP = 56 mmHg (MAP - ICP = 80 - 24, which is critically below the 60–70 mmHg Brain Trauma Foundation target, while ICP > 20–22 mmHg is elevated); Cushing's Triad of impending brainstem herniation consists of (1) Widening pulse pressure (systolic hypertension), (2) Reflex Bradycardia, and (3) Irregular respirations (Cheyne-Stokes); treat elevated ICP with HOB at 30° neutral midline neck, CSF drainage via EVD, and IV Hypertonic Saline (3%) or Mannitol (holding Mannitol if Serum Osmolality > 320 mOsm/kg or Osmolar Gap > 10–15) — (1) MAP = [SBP + 2(DBP)] / 3 = (110 + 130) / 3 = 80 mmHg. (2) CPP = MAP - ICP = 80 - 24 = 56 mmHg (normal ICP is 5–15 mmHg; treat ICP > 20–22 mmHg and maintain CPP between 60 and 70 mmHg). (3) Cushing's Triad (late sign of brainstem compression/herniation) is the exact OPPOSITE of hypovolemic shock: Systolic Hypertension with Widening Pulse Pressure + Bradycardia + Irregular Respirations. (4) Notice that CO_2 is a potent cerebral vasodilator: hypercapnia spikes ICP, whereas extreme prophylactic hyperventilation (PaCO_2 < 25 mmHg) causes severe cerebral vasoconstriction and brain ischemia (keep PaCO_2 35–40 mmHg, using brief target 30–35 mmHg only as a temporary bridge during acute herniation). ✓; D) Place the patient flat (0° supine) with the neck flexed and administer hypotonic 0.45% NaCl IV fluids |
| 31 | What is the official examination format, question count, appointment duration, and reference handbook rule for the NCEES Fundamentals of Engineering (FE CBT) examination, and what are the four steps to US Professional Engineer (PE) licensure? | The NCEES FE CBT exam consists of 110 questions (100 scored + 10 unscored pretest items, using MCQ and Alternative Item Types) in a 6-hour total appointment (5 hours 20 minutes of actual exam time with a scheduled 25-minute break), using the searchable electronic NCEES FE Reference Handbook as the only permitted reference; the 4-step PE pathway requires: (1) an EAC/ABET-accredited engineering degree, (2) passing the FE exam (EIT/EI certification), (3) 4 years of progressive qualifying engineering experience under a licensed PE, and (4) passing the discipline-specific NCEES PE exam — Administered year-round via Pearson VUE CBT, the NCEES FE exam contains 110 items across a 5-hour-20-minute testing window (within a 6-hour appointment) with onscreen access to the NCEES FE Reference Handbook. Full PE licensure (authority to sign, seal, and take responsible charge of engineering plans for the public) requires an ABET degree, FE pass (EIT/EI), 4 years of progressive engineering experience under a PE, and passing the PE exam. | Administered year-round via Pearson VUE CBT, the NCEES FE exam contains 110 items across a 5-hour-20-minute testing window (within a 6-hour appointment) with onscreen access to the NCEES FE Reference Handbook. Full PE licensure (authority to sign, seal, and take responsible charge of engineering plans for the public) requires an ABET degree, FE pass (EIT/EI), 4 years of progressive engineering experience under a PE, and passing the PE exam. | A) The NCEES FE exam consists of 180 questions over 8 hours open-book with any personal textbooks permitted, and requires 2 years of experience before sitting the FE; B) The NCEES FE CBT exam consists of 110 questions (100 scored + 10 unscored pretest items, using MCQ and Alternative Item Types) in a 6-hour total appointment (5 hours 20 minutes of actual exam time with a scheduled 25-minute break), using the searchable electronic NCEES FE Reference Handbook as the only permitted reference; the 4-step PE pathway requires: (1) an EAC/ABET-accredited engineering degree, (2) passing the FE exam (EIT/EI certification), (3) 4 years of progressive qualifying engineering experience under a licensed PE, and (4) passing the discipline-specific NCEES PE exam — Administered year-round via Pearson VUE CBT, the NCEES FE exam contains 110 items across a 5-hour-20-minute testing window (within a 6-hour appointment) with onscreen access to the NCEES FE Reference Handbook. Full PE licensure (authority to sign, seal, and take responsible charge of engineering plans for the public) requires an ABET degree, FE pass (EIT/EI), 4 years of progressive engineering experience under a PE, and passing the PE exam. ✓; C) The NCEES FE exam has 80 questions in 4 hours and grants immediate authority to stamp and seal public engineering drawings upon passing; D) Passing the FE exam automatically waives the PE exam after 5 years of construction management experience |
| 32 | Compare the official examination structures and passing scaled scores of the AANP FNP-C, ANCC FNP-BC, and AACN CCRN (Adult) certification examinations. | AANP FNP-C: 150 questions (135 scored + 15 unscored pretest) in 3 hours, passing scaled score 500 out of 800 (focused 100% on clinical domains: Assessment, Diagnosis, Plan, Evaluation across the lifespan); ANCC FNP-BC: 175 questions (150 scored + 25 unscored pretest) in 3.5 hours, passing scaled score 350 out of 500 (includes clinical domains plus Professional Role, Policy, and Evidence-Based Practice); AACN CCRN: 150 questions (125 scored + 25 unscored pretest) in 3 hours, weighted 80% Clinical Judgment and 20% Professional Caring and Ethical Practice (AACN Synergy Model) — FNP candidates choose between two national board exams: AANP FNP-C (150 items: 135 scored / 15 pretest, 3 hrs, 500/800 pass score, pure clinical decision-making across Assessment 36%, Diagnosis 24%, Plan 23%, Evaluation 17%) and ANCC FNP-BC (175 items: 150 scored / 25 pretest, 3.5 hrs, 350/500 pass score, testing clinical practice alongside professional role/health policy). The AACN CCRN exam (150 items: 125 scored / 25 pretest, 3 hrs) tests acute/critical care nursing (80% Clinical Judgment across organ systems + 20% Professional Caring/Ethical Practice). | FNP candidates choose between two national board exams: AANP FNP-C (150 items: 135 scored / 15 pretest, 3 hrs, 500/800 pass score, pure clinical decision-making across Assessment 36%, Diagnosis 24%, Plan 23%, Evaluation 17%) and ANCC FNP-BC (175 items: 150 scored / 25 pretest, 3.5 hrs, 350/500 pass score, testing clinical practice alongside professional role/health policy). The AACN CCRN exam (150 items: 125 scored / 25 pretest, 3 hrs) tests acute/critical care nursing (80% Clinical Judgment across organ systems + 20% Professional Caring/Ethical Practice). | A) Both AANP and ANCC FNP exams have 200 questions in 4 hours with a passing score of 75%, and CCRN is weighted 50% clinical / 50% hospital administration; B) AANP FNP-C includes drag-and-drop and oral OSCE stations, whereas ANCC FNP-BC has 100 scored questions; C) AANP FNP-C: 150 questions (135 scored + 15 unscored pretest) in 3 hours, passing scaled score 500 out of 800 (focused 100% on clinical domains: Assessment, Diagnosis, Plan, Evaluation across the lifespan); ANCC FNP-BC: 175 questions (150 scored + 25 unscored pretest) in 3.5 hours, passing scaled score 350 out of 500 (includes clinical domains plus Professional Role, Policy, and Evidence-Based Practice); AACN CCRN: 150 questions (125 scored + 25 unscored pretest) in 3 hours, weighted 80% Clinical Judgment and 20% Professional Caring and Ethical Practice (AACN Synergy Model) — FNP candidates choose between two national board exams: AANP FNP-C (150 items: 135 scored / 15 pretest, 3 hrs, 500/800 pass score, pure clinical decision-making across Assessment 36%, Diagnosis 24%, Plan 23%, Evaluation 17%) and ANCC FNP-BC (175 items: 150 scored / 25 pretest, 3.5 hrs, 350/500 pass score, testing clinical practice alongside professional role/health policy). The AACN CCRN exam (150 items: 125 scored / 25 pretest, 3 hrs) tests acute/critical care nursing (80% Clinical Judgment across organ systems + 20% Professional Caring/Ethical Practice). ✓; D) AACN CCRN tests outpatient primary care pediatrics and prenatal care across 175 questions |

---
Study this deck interactively with FSRS-6 spaced repetition, audio review, and multiple-choice mode at [Flashcards World](https://flashcards.world/flashcards/sets/c0c44ccc-d333-44ac-a142-c40f08101356/).